Unit bibliography

TEAM 1 – The one carbon metabolism and epigenomics in the developmental origins of inherited and complex disease

1. Antunez C, Barbaud A, Gomez E, Audonnet S,Lopez S, Gueant-Rodriguez RM, Aimone-Gastin I, Gomez F, Blanca M, Gueant JL
   Recognition of iodixanol by dendritic cells increases the cellular response in delayed allergic reactions to contrast media.
   Exp. All., 2011, 41, 657-664
2. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND-2 investigators (dont Bronowicki JP).
   Boceprevir for previously treated chronic HCV genotype 1 infection.
   Engl. J. Med., 2011, 364, 1207-1217
3. Beneteau, C., E. Landais, M. Doco-Fenzy, C. Gavazzi, C. Philippe, M. Beri-Dexheimer, C. Bonnet, J. Vigneron, P. Walrafen, J. Motte, B. Leheup and P. Jonveaux
   Microtriplication of 11q24.1: a highly recognisable phenotype with short stature, distinctive facial features, keratoconus, overweight, and intellectual disability.
   Journal of Medical Genetics. 2011, 48, 635-639.
4. Bonnet, C., M. Grati, S. Marlin, J. Levilliers, J. P. Hardelin, M. Parodi, M. Niasme-Grare, D. Zelenika, M. DelePine, D. Feldmann, L. Jonard, A. El-Amraoui, D. Weil, B. Delobel, C. Vincent, H. Dollfus, M. M. Eliot, A. David, C. Calais, J. Vigneron, B. Montaut-Verient, D. Bonneau, J. Dubin, C. Thauvin, A. Duvillard, C. Francannet, T. Mom, D. Lacombe, F. Duriez, V. Drouin-Garraud, M. F. Thuillier-Obstoy, S. Sigaudy, A. M. Frances, P. Collignon, G. Challe, R. Couderc, M. Lathrop, J. A. Sahel, J. Weissenbach, C. Petit and F. Denoyelle
   Complete exon sequencing of all known Usher syndrome genes greatly improves molecular diagnosis.
   Orphanet Journal of Rare Diseases. 2011, 6.
5. Brunaud, L. and P. Angelos
   Robot-assisted endoscopic thyroidectomy: Should Theodore Kocher’s approach be definitively buried?
   Journal of Visceral Surgery. 2011, 148, E403-E404.
6. Brunaud, L., N. Reibel and A. Ayav
   Pancreatic, endocrine and bariatric surgery: The role of robot-assisted approaches.
   Journal of Visceral Surgery. 2011, 148, E47-E53.
7. Chen M, Peyrin-Biroulet L, George A, Coste F, Bressenot A, Bossenmeyer-Pourie C, Alberto JM, Xia B, Namour B, Gueant JL
   Methyl deficient diet aggravates experimental colitis in rats.
   Cell. Mol. Med., 2011, 15, 2486-2497
8. Forges T, Monnier P, Leheup B, Cheillan D, Brivet M, Barbarino A, Gueant JL, Feillet F
   Ovarian tissue cryopreservation and subsequent spontaneous pregnancies in a patient with classic galactosemia.
   Steril., 2011, 95, 290. e1-3
9. Germain, A., N. Reibel and L. Brunaud
   Totally robotic gastric bypass.
   Journal of Visceral Surgery. 2011, 148, E267-E272.
10. Gnimpieba EZ, Eveillard D, Guéant JL, Chango A
    Using logic programming for modeling the one-carbon metabolism network to study the impact of folate deficiency on methylation processes.
    Molecular BioSystems, 2011, 7, 2508-2521

11. Guéant-Rodriguez RM, Juillière Y, Battaglia-Hsu SF, Debard R, Gérard P, Reyes P, Danchin N, Guéant JL
    Association of ILB polymorphism with left ventricular systolic dysfunction : a relation with the release of inteleukin-1b in stress condition.
    Genomics, 2011, 21, 579-586
12. Gueant-Rodriguez RM, Spada R, Moreno-Garcia M, Anello G, Bosco P, Lagrost L, Romano A, Elia M, Gueant JL
    Homocysteine is a determinant of ApoA-I and both are associated with Ankle Brachial Index, in an Ambulatory Elderly Population.
    Atheroslerosis, 2011, 214, 480-485
13. Kimmoun A, Munagamage G, Dessalles N, Gerard A, Feillet F, Levy B.
    Unexpected awakening from comatose thyroid storm after a single intravenous injection of L-carnitine.
    Intensive Care Med. 2011, 37, 1716-1717
14. MacDonald A, Rocha JC, van Rijn M, Feillet F
    Nutrition in phenylketonuria.
    Genet. Metab. 2011, 104, Suppl:S10-8
15. Moreno-Garcia M, Guéant-Rodriguez RM, Pooya S, Brachet P, Alberto JM, Jeannesson E, Mskali F, Gueguen N, Marie PY, Lacolley P, Hermann MA, Juilliere Y, Malthiery Y, Guéant JL.
    Methyl donor deficiency produces a cardiomyopathy related to imbalanced methylation/acetylation of PGC-1a by PRMT1 and SIRT1 in the rat.
    Pathol., 2011, 225, 324-335
16. Namour F, Dobrovoljski G, Chery C, Audonnet S, Feillet F, Sperl W, Guéant JL
    Luminal expression of cubilin is impaired in Imerslund Grasbeck syndrome with compound AMN mutations in intron 3 and exon 7
    Haematologica, 2011, 96, 1715-1719
17. Oussalah A, Guéant JL, Peyrin-Biroulet L
    Meta-analysis hyperhomocysteinaemia in inflammatory bowel diseases
    Pharmacol. Ther., 2011, 34, 1173-1184
18. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 investigators.
    Boceprevir for untreated chronic HCV genotype 1 infection.
    Engl. J. Med., 2011, 364, 1195-1206
19. Quilliot D, Forbes A, Dubois F, Gueant JL, Ziegler O
    Carotenoid deficiency in chronic pancreatitis : the effect of an increase in tomato consumption.
    J; Clin. Nut., 2011, 65, 262-268
20. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J; FRESGUN (don’t Bronowcki JP)
    A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
    Hepatol., 2011, 54, 1011-1009
21. Remen T, Acouetey D, Coevet V, Paris C, Guéant-Rodriguez RM, Guéant JL, Zmirou-Navier D. Early symptoms oa airways inflammation among young bakers, pastry cooks and hairdressers. Epidemiology, 2011, 22, 1 (suppl.), S27
22. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team (dont Bronowicki JP)
    Telaprevir for retreatment of HCV infection
    Engl. J. Med., 2011, 364, 2417-2428
23. Akchiche N, Bossenmeyer-Pourié C, Kerek R, Martin N, Pourié G, Koziel V, Helle D, Alberto JM, Ortiou S, Camadro JM, léger T, Guéant JL, Daval JL
    Homocusteinylation of neuronal proteins contributes to folate deficiency-associated alterations of differenciation, vesicular transport , and plasticity in hippocampal neurnal cells.
    FASEB J., 2012, 26, 3980-3992
24. Beck B, Bossenmeye-Pourié C, Jeannesson E, Richy S, Guéant JL
    Increased homocysteinemia is associated with beneficial effects on body weight after long-term high-protein, low-fat diet in rats ;
    Nutrition, 2012, 28, 932-936
25. Bonnet, C., A. Masurel-Paulet, A. A. Khan, M. Beri-Dexheimer, P. Callier, F. Mugneret, C. Philippe, C. Thauvin-Robinet, L. Faivre and P. Jonveaux.
    Exploring the Potential Role of Disease-Causing Mutation in a Gene Desert: Duplication of Noncoding Elements 5 ‘ of GRIA3 is Associated with GRIA3 Silencing and X-Linked Intellectual Disability. Human Mutation. 2012, 33, 355-358.
26. Coelho D*, Kim JC*, Miousse IR, Fung S, du Moulin M, Buers I, Suormala T, Burda P, Frapolli M, Stucki M, Nürnberg P, Thiele H, Robenek H, Höhne W, Longo N, Pasquali M, Mengel E, Watkins D, Shoubridge EA, Majewski J, Rosenblatt DS, Fowler B, Rutsch F, Baumgartner MR.
    Mutations in ABCD4 cause a new inborn error of vitamin B12 metabolism.
    Nature Genetics, 2012, 44, 1152-1155  *co-premiers auteurs
27. Cornejo-Garcia JA, Guéant-Rodriguez RM, Torres MJ, Blanca-Lopez N, Tramoy D, Romano A, Blanca M, Guéant JL
    Biological and genetic determinants of atopy are predictors of immediate-type allergy to betalactams, in Spain
    Allergy, 2012, 67, 1181-1185
28. Cornejo-Garcia JA, Jagemann LR, Blanca-Lopez N, Dona I, Flores C, Guéant-Rodriguez RM, Torres MJ, Fernandez J, Laguna JJ, Rosado A, Agundez JA, Garcia-Martin E, Canto G, Guéant JL, Blanca M
    Genetic variants of the arachidonic acid pathway in non-steroid anti-inflammatory drug-induced acute urticaria.
    Exp. Allergy, 2012, 42, 1772-1781
29. Drid N, Groussel R, Belhocine K, Salah A, Oussalah A.
    Upper gastrointestinal endoscopy for hematemesis in a patient aged 117 years.
    Endoscopy, 2012, 44 Suppl 2 UCTN:E333
30. Gimm, O., C. DeMicco, A. Perren, F. Giammarile, M. K. Walz and L. Brunaud.
    Malignant pheochromocytomas and paragangliomas: a diagnostic challenge. Langenbecks Archives of Surgery. 2012, 397, 155-177.
31. Guéant-Rodriguez RM, Spada R, Pooya S, Jeannesson E, Moreno-Garcia MA, Anello G, Bosco P, Elia M, Romano A, Alberto JM, Juilière Y, Guéant Jl
    Homocysteine predicts increased NT-pro BNP through impaired fatty acid oxidation.
    J. Cardiol., 2012, 167, 768-775
32. Guéchot J, Trocmé C, Renversez JC, Sturm N, Zarski JP; ANRS HC EP 23 Fibrostar Study Group (dont Bronowicki JP)
    Independent validation of the Enhanced Liver Fibrosis (ELF) score in the ANRS HC EP 23 Fibrostar cohort of patients with chronic hepatitis C
    Chem. Lab. Med., 2012, 50, 693-699
33. Huynh, M. T., M. Beri-Dexheimer, C. Bonnet, M. Bronner, A. A. Khan, L. Allou, C. Philippe, J. Vigneron and P. Jonveaux
    RUNX1T1, a chromatin repression protein, is a candidate gene for autosomal dominant intellectual disability.
    American Journal of Medical Genetics. 2012, Part A. 158A, 1782-1784.
34. Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, lbrecht JK, Bronowicki JP
    Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with bocepervir and peginterferon/ribavirin;
    Hepatology, 2012, 56, 567-575
35. Marguerite V, Gkikopoulou E, Alberto JM, Guéant JL, Merten M
    Phospholipase D activation mediates cobalamin-induced downregulation of Multidrug resistance-1 gene and increase in sensitivity to vinblastine in HepG2 cells.
    J. Biochem. Cell. Biol., 2012, 45, 213-220
36. Martin N, Bossenmeyer-Pourié C, Koziel V, Jazi R, Audonnet S, Vert P, Guéant JL, Daval JL, Pourié G
    Non-injurious neonatal hypoxia confers resistance to brain senescence in aged male rats.
    PLoS one, 2012, 7, e48828
37. Oussalah A., Besseau C, Chery C, Jeannesson E, Guéant-Rodriguez RM, Anello G, Bosco P, Elia M, Romano A, Bronowicki JP, Gerard P, Paoli J, Avogbé PH, Chabi N, Sanni A, Amouzou E, Peyrin-Biroulet L, Guéant JL
    Helicobacter pylori serologic status has no influence on the association between ucosyltransferase 2 polymorphism (FUT2 461 G->A) and vitamin B12 in Europe and West Africa
    J. Clin. Nutr., 2012, 95, 514-521
38. Pellanda H, Forges T, Bressenot A, Chango A, Bronowicki JP, Guéant JL, Namour F
    Fumonisin FB1 treatment acts synergistically with donor deficiency during rat pregnancy to produce alterations of H3- and H4-histone methylation patterns in fetuses.
    Nutr. Food. Res., 2012, 56, 976-985
39. Pellanda H, Namour F, Fofou-Caillierez,M, Bressenot A, Alberto JM, Chéry C, Ayav A, Bronowicki JP, Guéant JL, Forges T
    A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma.
    J. Biochem. Cell. Biol., 2012, 44, 385-392
40. Piard, J., A. Verloes, H. Cave, M. Peuchmaur, S. Bennaceur and B. Leheup ()
    Extensive abdominal lipomatosis in a patient with Noonan/LEOPARD syndrome (Noonan syndrome-Multiple Lentigines).
    American Journal of Medical Genetics. 2012, Part A. 158A, 1406-1410.
41. Pooya S, Blaise S, Moreno-Garcia M, Giudicelli J, Alberto JM, Guéant-Rodriguez RM, Jeannesson E, Gueguen N, Bressenot A, Nicolas B, Malthiery Y, Daval JL, Peyrin-Biroulet L, Bronowici JP, Guéant JL
    Methyl donor deficiency impairs fatty acid oxidation through PGC-1a hypomehtylation and decreased ER-a, ERR-a and HNF-4a in the rat liver.
    Hepatol., 2012, 57, 344-351
42. Acouetey DS, Zmirou-Nvier D, Avogbe PH, Tossa P, Remen T, Barbaud A, Cornejo-Garcia JA, Blanca M, Bohadana A, Paris C, Guéant JL, Guéant-Rodriguez RM
    Genetic preditors of inflammation in the risk of ccupational asthma in young apprentices
    Allergy Astham Immunol., 2013, 110, 423-428
43. Auger J, Bonnet C, Valduga M, Philippe C, Bertolo-Houriez E, Beri-Dexheimer M, Schweitzer C, Leheup B, Jonveaux P.
    De novo complex X chromosome rearrngement unmasking maternally inherited CSF2RA deletion in a girl with pulmonary alveolar proteinosis.
    J. Med. Genet. A, 2013, 161, 2594-2599
44. Benizri EI, Renaud M, Reibel N, Germain A, Ziegler O, Zarnegar R, Ayav A, Bresler L, Brunaud L.
    Perioperative outcomes after totally robotic gastric bypass: a prospective nonrandomized controlled study.
    J. Surg., 2013, 206, 145-151
45. Bonnet C, Ali Khan A, Bresso E, Vigouroux C, Béri M, Lejczak S, Deemer B, Andrieux J, Philippe C, Moncla A, Giurgea I, Devignes MD, Leheup B, Jonveaux P.
    Extended spectrum of MBD5 mutations in neurodevelopmental disorders
    J. Hum. Genet., 2013, 21, 1457-1461
46. Bossenmeyer-Pourié C, Pourié G, Koziel V, Helle D, Jeannesson E, Guéant JL, Beck B
    Early methyl donor deficiency produces severe gastritis in mothers and offspring through N-homocysteinylation of cytoskeleton proteins, cellular stress and inflammation
    The Faseb J., 2013, 27, 2185-2197
47. Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP
    How to optimize HCV therapy in genotype 1 patients with cirrhosis
    Liver Int., 2013, 33, Suppl 1, 46-55
48. Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, Morris DW, Younes Z, Fried MW, Bourlière M, Hézode C, Reddy KR, Massoud O, Abrams GA, Ratziu V, He B, Eley T, Ahmad A, Cohen D, Hindes R, McPhee F, Reilly B, Mendez P, Hughes E
    Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C
    Ther., 2013, 18, 885-893
49. Brunaud L
    Will watching videos make us better surgeons?
    J Visc Surg, 2013, 150, 295-296
50. Brunaud L.
    Should all new surgical procedures be published?
    Visc. Surg., 2013, 150, 163-16
51. Bursztejn AC, Romano A, Guéant-Rodriguez RM, Cornejo JA, Oussalah A, Chery C, Gastin I, Gaeta F, Barbaud A, Blanca M, Guéant JL
    Allergy to betalactams and nucleotide-binding oligomerization domain (NOD) gene polymorphisms;
    Allergy, 2013, 68, 1076-1080
52. Chery C, Hehn A, Mrabet N, Oussalah A, Jeannesson E, Besseau C, Alberto JM, Gross I, Josse T, Gérard P, Guéant-Rodriguez RM, Freund JN, Devignes J, Bougaud F, Peyrin-Biroulet L, Feillet F, Guéant JL
    Gastric intrinsic factor deficiency with combined GIF heterozygous mutations and FUT2 secertor variant.
    Biochimie, 2013, 95, 995-1001
53. Dong S, Acouetey DS, Guéant-Rodriguez RM, Zmirou-Navier D, Rémen T, Blanca M, Mertes PM, Guéant JL
    Prevalence of IgE against neuromuscular blocking agents in hairdressers and bakers.
    ExP. Allergy, 2013, 43, 1256-1262
54. Fofou-Caillierez MB, Mrabet NT, Chery C, Dreumont N, Flayac J, Pupavac M, Paoli J, Alberto JM, Coelho D, Camadro JM, Feillet F, Watkins D, Fowler B, Rosenblatt DS, Guéant JL
    Interaction between methionine synthase isoforms and MMACHC : characterization in cblG-variant, cblG and cblC inherited causes of megaloblastic anaemia;
    Mol. Genet., 2013, 15, 4591-4601
55. Ghemrawi R , Pooya S, Lorentz S, Gauchotte G,  Arnold C, Guéant JL,  Battaglia-Hsu S^,
    Decreased vitamin B12 availability induces ER stress through impaired SIRT1-deacetylation of HSF1
    Cell Death & Disease,  2013, 4, e553
56. Guéant JL, Alpers DH
    Vitamin B12, a fascinating micronutriment, which influences human health in the very early and later stages of life.
    Biochimie, 2013, 95, 967-969
57. Guéant JL, Caillerez-Fofou M, Battaglia-Hsu S, Alberto JM, Freund JN, Dulluc I, Adjalla C, Maury F, Merle C, Nicolas JP, Namour F, Daval JL
    Molecular and cellular effects of vitamin B12 in brain, myocardium and liver through its role as co-factor of methionine synthase.
    Biochimie, 2013, 95, 1033-1040
58. Guéant JL, Namour F, Guéant-Rodriguez RM, Daval JL
    Folate and fetal programming : a plau in epigenomics ?
    Trends Endocrinol. Metab., 2013, 24, 279-289

59. Guéchot J, Boisson RC, Zarski JP, Sturm N, Calès P, Lasnier E; ANRS HCEP 23 Fibrostar Group (dont Bronowicki JP)
    AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations
    Res. Hepatol. Gastroenterol., 2013, 37, 467-472
60. Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group
    Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
    Hepatol., 2013, 59, 434-441
61. Kerek R, Geoffroy A, Bison A, Martin N, Akchiche N, Pourié G, Helle D, Guéant JL, Bossenmeyer-Pourié C, Daval JL
    Early methyl donor deficiency mau induce persistent brain defects by reducing Stat3 signaling targeted by miR-124.
    Cell Death Dis., 2013, 4, e755
62. Lammardo AM, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, Macdonald A, Dokoupil K, Ozel HG, Goyens P, Feillet F
    Main issues in micronutrient supplementation in phenylketonuria.
    Genet. Metab., 2013, 110, Suppl. S1-S5
63. Renaud M, Reibel N, Zarnegar R, Germain A, Quilliot D, Ayav A, Bresler L, Brunaud L.
    Multifactorial analysis of the learning curve for totally robotic Roux-en-Y gastric bypass for morbid obesity.
    Surg., 2013, 23, 1753-1760
64. Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, Macdonald A, Dokoupil K, Gokmen Ozel H, Lammardo AM, Goyens P, Feillet F
    Micronutrient status in phenylketonuria
    Genet. Metab., 2013, 110, Suppl. S6-S17
65. Trocello JM, Woimant F, El Balki S, Guichard JP, Poupon J, Chappuis P, Feillet F
    Extensive striatal, cortical and white matte brain MRI abnormalities in Wilson disease.
    Neurology, 2013, 81, 1557
66. Wiedemann A, Leheup B, Battaglia-Hsu SF, Jonveaux P, Jeannesson E, Feillet F
    Undiagnosed pheylketonuria in parents of phenylketonuric patients, is it worthwhile to be checked ?
    Genet. Metab., 2013, 11, suppl. S62-65

67. Barbaud A, Waton J, Herbeth B, Bursztejn AC, Bollaert M, Schmutz JL, Guéant-Rodriguez RM, Namour F, Guéant JL, Aimone-Gastin I
    Comparison of cytokine gene polymorphism in drug-induced maculopapular eruption, urticaria and drug reaction with eosinophilia and systemic symptoms (DRESS)
    Eur. Acad. Dermatol. Venerol., 2014, 28, 491-499
68. Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, Pol S, Terg R, Younes Z, He B, Eley T, Cohen D, Yu F, Hernandez D, McPhee F, Mendez P, Hughes E
    Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.
    J Hepatol. 2014, 61, 1220-1227
69. Brunaud L, Boutami M, Nguyen-Thi PL, Finnerty B, Germain A, Weryha G, Fahey TJ 3rd, Mirallie E, Bresler L, Zarnegar R.
    Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma
    Surgery, 2014, 156, 1410-1417; discussion1417-8
70. Brunaud, L.
    Publish your best videos in Journal of Visceral Surgery, an indexed journal! FOREWORD. Journal of Visceral Surgery. 2014,151, 151-151
71. Carrat F, Barthe Y, Hezode C, Fontaine H, Bronowicki JP
    Reply to: From the CUPIC study: great times are not coming (?).
    Hepatol., 2014, 60, 235-236
72. Chehadeh SE, Pourie G, Martin N, Alberto JM, Daval JL, Gueant JL, Leininger-Muller B
    Gestational methyl donor deficiency alters key proteins involved in neurosteroidogenesis in the olfactory bulbs of newborn female rats and is associated with impaired olfactory performance.
    British Journal of Nutrition. 2014, 111, 1021-1031
73. Chehadeh SEH, Dreumont N, Willekens J, Canabady-Rochelle L, Jeannesson E, Alberto JM, Daval JL, Gueant JL, Leininger-Muller B
    Early methyl donor deficiency alters cAMP signaling pathway and neurosteroidogenesis in the cerebellum of female rat pups.
    American Journal of Physiology-Endocrinology and Metabolism. 2014,307, E1009-E1019.
74. El Hajj Chehadeh S, Dreumont N, Willekens J, Canabady-Rochelle L, Jeannesson E, Alberto JM, Daval JL, Guéant JL, Leininger-Muller B
    Early methyl donor deficiency alters cAMP signaling pathway and neurosteroidogenesis in the cerebellum of female rat pups
    J. Physiol. Endocrinol. Metab. 2014, 307, E1009-1019
75. El Hajj Chehadeh S, Pourié G, Martin N, Alberto JM, Daval JL, Guéant JL, Leininger-Muller B
    Gestational methyl donor deficiency alters key proteins involved in neurosteroidogenesis in the olfactory bulbs of newborn female rats is associated with impaired olfactory performance.
    J. Nutr., 2014, 111, 1021-1031
76. Elakoum R, Gauchotte G, Oussalah A, Wissler MP, Clément-Duchâne C, Vignaud JM, Guéant JL, Namour F
    CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.
    Biochimie, 2014, 97, 201-218
77. Fantola G, Perrenot C, Frisoni R, Germain A, Ayav A, Bresler L, Brunaud L
    Robotic Roux-en-Y gastric bypass surgical simulation curriculum
    Obes Surg, 2014, 24, 1833-1834
78. Feillet F, Muntau AC, Debray FG, Lotz-Havla AS, Puchwein-Schwepcke A, Fofou-Caillierez MB, van Spronsen F, Trefz FF
    Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases
    Inherit. Metab. Dis., 2014, 37, 753-762
79. Guéant JL, Dong S, Guéant-Rodriguez RM, Blanca M, Mertes PM
    Reply to J. Leysen et al.
    Exp. Allergy, 2014, 44, 456
80. Guéant JL, Elakoum R, Ziegler O, Coelho D, Feigerlova E, Daval JL, Guéant-Rodriguez RM
    Nutritional models of foetal programming and nutrigenmic and epigenomic dysregualtions of fatty acid metabolism in the liver and heart.
    Pflugers Arch., 2014, 466, 833-850
81. Hezode C, Fontaine H, Barthe Y, Carrat F, Bronowicki JP
    Reply To : From the CUPIC study : Great times are not coming (?) »
    Hepatol., 2014, 60, 900-901
82. Quilliot D, Zallot C, Malgras , Germain A, Bresler L, Ayav A, Bigard MA, Peyrin-Biroulet L, Ziegler O
    Self-insertion of a nasogastric tube for home enteral nutrition : a pilot study.
    Parenter. Enteral. Nutr., 2014,38, 895-900
83. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP
    Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
    Hepatol., 2014, 60, 748-756
84. Fantola G, Reibel N, Brunaud L
    Robotic-assisted laparoscopic bilio-pancreatic bypass with duodenal switch
    Visc. Surg., 2015, 152, 251-256
85. Guéant JL, Romano A, Cornejo-Garcia JA, Oussalah A, Chery C, Blanca-López N, Guéant-Rodriguez RM, Gaeta F, Rouyer P, Josse T, Canto G, Carmona FD, Bossini-Castillo L, Martin J, Laguna JJ, Fernandez J, Feo F, Ostrov DA, Plasencia PC, Mayorga C, Torres MJ, Blanca M
    HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping
    Allergy Clin. Immunol., 2015, 135, 253-259
86. Jeannesson-Thivisol E, Feillet F, Chéry C, Perrin P, Battaglia-Hsu SF, Herbeth B, Cano A, Barth M, Fouilhoux A, Mention K, Labarthe F, Arnoux JB, Maillot F, Lenaerts C, Dumesnil C, Wagner K, Terral D, Broué P, de Parscau L, Gay C, Kuster A, Bédu A, Besson G, Lamireau D, Odent S, Masurel A, Guéant JL, Namour F
    Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness
    Orphanet J. Rare Dis., 2015, 10, 158
87. Makdissy N, Haddad K, Mouawad C, Popa I, Younsi M, Valet P, Brunaud L, Ziegler O, Quilliot D
    Regulation of SREBPs by Sphingomyelin in Adipocytes via a Caveolin and Ras-ERK-MAPK-CREB Signaling Pathway
    PLoS One, 2015, 10, e0133181
88. Melhem H, Hansmannel F, Bressenot A, Battaglia-Hsu SF, Billioud V, Alberto JM, Gueant JL, Peyrin-Biroulet L.
    Methyl-deficient diet promotes colitis and SIRT1-mediated endoplasmic reticulum stress
    Gut, 2016, 65, 595-606
89. Mignot C, Lambert L, Pasquier L, Bienvenu T, Delahaye-Duriez A, Keren B, Lefranc J, Saunier A, Allou L, Roth V, Valduga M, Moustaïne A, Auvin S, Barrey C, Chantot-Bastaraud S, Lebrun N, Moutard ML, Nougues MC, Vermersch AI, Héron B, Pipiras E, Héron D, Olivier-Faivre L, Guéant JL, Jonveaux P, Philippe C
    WWOX-related encephalopathies: delineation of the phenotypical spectrum and emerging genotype-phenotype correlation
    Med. Genet. 2015, 52, 61-70
90. Oussalah A, Bosco P, Anello G, Spada R, Guéant-Rodriguez RM, Chery C, Rouyer P, Josse T, Romano A, Elia M, Bronowicki JP, Guéant JL
    Exome-Wide Association Study Identifies New Low-Frequency and Rare UGT1A1 Coding Variants and UGT1A6 Coding Variants Influencing Serum Bilirubin in Elderly Subjects: A Strobe Compliant Article
    Medicine (Baltimore). 2015, 94, e925
91. Oussalah A, Ferrand J, Filhine-Tresarrieu P, Aissa N, Aimone-Gastin I, Namour F, Garcia M, Lozniewski A, Guéant JL
    Diagnostic Accuracy of Procalcitonin for Predicting Blood Culture Results in Patients With Suspected Bloodstream Infection: An Observational Study of 35,343 Consecutive Patients (A STROBE-Compliant Article).
    Medicine (Baltimore), 2015, 94, e1774
92. Oussalah A, Fournier JP, Guéant JL, Braun M
    Information-seeking behavior during residency is associated with quality of theoretical learning, academic career achievements, and evidence-based medical practice: a strobe-compliant article
    Medicine (Baltimore),.2015, 94, e535
93. Pourié G, Martin N, Bossenmeyer-Pourié C, Akchiche N, Guéant-Rodriguez RM, Geoffroy A, Jeannesson E, Chehadeh SE, Mimoun K, Brachet P, Koziel V, Alberto JM, Helle D, Debard R, Leininger B, Daval JL, Guéant JL
    Folate- and vitamin B12-deficient diet during gestation and lactation alters cerebellar synapsin expression via impaired influence of estrogen nuclear receptor α
    FASEB J., 2015, 29, 3713-3725
94. Sessa L, Nomine C, Germain A, Ayav A, Bresler L, Brunaud L
    Right robotic adrenalectomy for a 8cm pheochromocytoma (with video).
    J Visc Surg. 2015 Nov;152(5):334-5

95. Agopiantz M, Journeau P, Lebon-Labich B, Sorlin A, Cuny T, Weryha G, Leheup B
    McCune-Albright syndrome, natural history and multidisciplinary management in a series of 14 pediatric cases
    Endocrinol. (Paris), 2016, 77, 7-13
96. Allou L, Julia S, Amsallem D, El Chehadeh S, Lambert L, Thevenon J, Duffourd Y, Saunier A, Bouquet P, Pere S, Moustaïne A, Ruaud L, Roth V, Jonveaux P, Philippe C
    Rett-like phenotypes: expanding the genetic heterogeneity to the KCNA2 gene and first familial case of CDKL5-related disease
    Clin Genet, 2016 Apr 7, doi: 10.1111/cge.12784
97. Allou L, Lambert L, Amsallem D, Bieth E, Edery P, Destree A, Rivier F, Amor D, Thompson E, Nicholl J, Harbord M, Nemos C, Saunier A, Moustaine A, Vigouroux A, Jonveaux P and Philippe C.
    14q12 and severe Rett-like phenotypes: new clinical insights and physical mapping of FOXG1-regulatory elements. European Journal of Human Genetics, 2012, 20, 1216-1223
98. Beck B and Pourie G.
    Ghrelin, neuropeptide Y, and other feeding-regulatory peptides active in the hippocampus: role in learning and memory.
    Nutrition Reviews, 2013, 71, 541-561.
99. Beck B, Richy S, Archer ZA and Mercer JG.
    Early and persistent up-regulation of hypothalamic orexigenic peptides in rat offspring born to dams fed a high-carbohydrate supplement during gestation. Brain Research, 2012, 1477, 10-18.
100. Beck B, Richy S, Archer ZA and Mercer JG.
     Ingestion of carbohydrate-rich supplements during gestation programs insulin and leptin resistance but not body weight gain in adult rat offspring. Frontiers in Physiology, 2012, 3.
101. Bereziat G and Gueant J-L. Untitled.
     Biochimie, 2016,125,232-233.
102. Béréziat G, Guéant JL
     Editorial
     Biochimie, 2016 Apr 8. pii: S0300-9084(16)30049-9. doi: 10.1016/j.biochi.2016.04.006. [Epub ahead of print]
103. Brunaud L, Fuchs-Buder T
     In response to « Reversal of rocuronium-induced neuromuscular blockade by sugammadex allows for optimization of neural monitoring of the recurrent laryngeal nerve ».
     Laryngoscope, 2016, Apr 14. doi: 10.1002/lary.25990
104. Brunaud L, Nomine-Criqui C, Germain A, Ayav A, Bresler L
     Comments on: Clinical predictors of prolonged postresection hypotension after laparoscopic adrenalectomy for pheochromocytoma
     Surgery, 2016, 160, 250
105. Brunaud, L., P. L. Nguyen-Thi, E. Mirallie, M. Raffaelli, M. Vriens, P. E. Theveniaud, M. Boutami, B. M. Finnerty, W. Vorselaars, I. B. Rinkes, R. Bellantone, C. Lombardi, T. Fahey, R. Zarnegar and L. Bresler
     Predictive factors for postoperative morbidity after laparoscopic adrenalectomy for pheochromocytoma: a multicenter retrospective analysis in 225 patients.
     Surgical Endoscopy and Other Interventional Techniques. 2016, 30: 1051-1059.
106. Brunaud, L., Z. Li, K. Van Den Heede, T. Cuny and S. Van Slycke
     Endoscopic and robotic parathyroidectomy in patients with primary hyperparathyroidism.
     Gland Surgery. 2016, 5, 352-360.
107. Cornejo-Garcia JA, Romano A, Gueant-Rodriguez RM, Oussalah A, Blanca-Lopez N, Gaeta F, Tramoy D, Josse T, Dona I, Torres MJ, Canto G, Blanca M and Gueant JL.
     A non-synonymous polymorphism in galectin-3 lectin domain is associated with allergic reactions to beta-lactam antibiotics. Pharmacogenomics Journal, 2016,16, 79-82.
108. Feigerlova E, Demarquet L, Guéant L
     One carbon metabolism and bone homeostasis and remodeling: A review of experimental research and population studies
     Biochimie, 2016, 126, 115-123
109. Feigerlova E, Demarquet L, Melhem H, Ghemrawi R, Battaglia-Hsu SF, Ewu E, Alberto JM, Helle D, Weryha G, Guéant JL.
     Methyl donor deficiency impairs bone development via peroxisome proliferator-activated receptor-γ coactivator-1α-dependent vitamin D receptor pathway
     FASEB J., 2016 Jul 19. pii: fj.201600332R
110. Feigerlova E, Oussalah A, Fournier JP, Antonelli A, Hadjadj S, Marechaud R, Guéant JL, Roblot P, Braun M.
     Predictors of High Motivation Score for Performing Research Initiation Fellowship, Master 1, Research Master 2, and PhD Curricula During Medical Studies: A Strobe-Compliant Article
     Medicine (Baltimore), 2016, 95, 1-9
111. Geoffroy A, Kerek R, Pourié G, Helle D, Guéant JL, Daval JL, Bossenmeyer-Pourié C
     Late maternal folate supplementation rescues from methyl donor deficiency-associated  brain defects by restoring Let-7 and miT-34 pathways
     Neurobiol., 2016, Aug 17 [Epub ahead of print]
112. Goffinet L, Oussalah A, Guéant-Rodriguez RM, Chery C, Basha M, Avogbe PH, Josse T, Jeannesson E, Rouyer P, Flayac J, Gerard P, Le Touze A, Bonin-Goga B, Goga D, Simon E, Feillet F, Vikkula M, Guéant JL.
     Cystathionine β-synthase genetic variant rs2124459 is associated with a reduced risk of cleft palate in French and Belgian populations
     Med. Genet., 2016 Aug 17. pii: jmedgenet-2016-104111
113. Guéant JL
     One carbon metabolism, a complex metabolic network involved in pathomechanisms of inherited disorders, birth defects and age-related pathologies
     Biochimie, 2016, 126, 1-2
114. Hézode C, Bronowicki JP
     Ideal oral combinations to eradicate HCV: The role of ribavirin
     Hepatol., 2016, 64, 215-225.
115. Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Cernadas JR, Vultaggio A, Brockow K, Caubet JC, Makowska J, Nakonechna A, Romano A, Montañez MI, Laguna JJ, Zanoni G, Gueant JL
     In vitro tests for Drug Hypersensitivity Reactions. An ENDA/EAACI Drug Allergy Interest Group Position Paper.
     Allergy, 2016 , 71, 1103-1134
116. Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL, Study Group FT.
     BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease
     Oncotarget, 2016 Aug 17. doi: 10.18632
117. Oussalah A, Mayorga C, Blanca M, Barbaud A, Nakonechna A, Cernadas J, Gotua M, Brockow K, Caubet JC, Bircher A, Atanaskovic M, Demoly P, Kase-Tanno L, Terreehorst I, Laguna JJ, Romano A, Guéant JL; Task force “Genetic predictors of drug hypersensitivity” of the European Network on Drug Allergy (ENDA) of EAACI
     Genetic variants associated with drugs-induced immediate hypersensitivity reactions: a PRISMA-compliant systematic review
     Allergy, 2016, 17, 443-462. [Epub ahead of print] Review
118. Peng L, Dreumont N, Coelho D, Guéant JL, Arnold C
     Genetic animal models to decipher the pathogenic effects of vitamin B12 and folate deficiency
     Biochimie, 2016, 126, 43-51
119. Preiser J-C, Fraipont V and Quilliot D.
     Trial of the Route of Early Nutritional Support in Critically Ill Adults.
     New Engl. J. Med., 2015, 372, 487-488.
120. Reddon H, Guéant JL, Meyre D
     The importance of gene-environment interactions in human obesity
     Sci. (Lond). 2016 Sep 1;130(18):1571-97
121. Sohani, Z. N., S. Sarma, A. Alyass, R. J. de Souza, S. Robiou-du-Pont, A. Li, A. Mayhew, F. Yazdi, H. Reddon, A. Lamri, C. Stryjecki, A. Ishola, Y. K. Lee, N. Vashi, S. S. Anand and D. Meyre
     Empirical evaluation of the Q-Genie tool: a protocol for assessment of effectiveness.
     Bmj Open. 2016, 6.
122. Sorlin A, Briand G, Cheillan D, Wiedemann A, Montaut-Verient B, Schmitt E, Feillet F
     Effect of l-Arginine in One Patient with Peroxisome Biogenesis Disorder due to PEX12 Deficiency
     Neuropediatrics, 2016 Jun;47(3):179-81
123. Valduga M, Philippe C, Lambert L, Bach-Segura P, Schmitt E, Masutti JP, Francois B, Pinaud P, Vibert M and Jonveaux P.
     WWOX and severe autosomal recessive epileptic encephalopathy: first case in the prenatal period.
     Human Genet., 2015, 60, 267-27
124. Van Maldergem L, Hou Q, Kalscheuer VM, Rio M, Doco-Fenzy M, Medeira A, de Brouwer APM, Cabrol C, Haas SA, Cacciagli P, Moutton S, Landais E, Motte J, Colleaux L, Bonnet C, Villard L, Dupont J and Man H-Y.
     Loss of function of KIAA2022 causes mild to severe intellectual disability with an autism spectrum disorder and impairs neurite outgrowth.
     Mol. Genet., 2013, 22, 3306-3314.

125. Boutron A, Acquaviva C, Vianey-Saban C, de Lonlay P, de Baulny HO, Guffon N, Dobbelaere D, Feillet F, Labarthe F, Lamireau D, Cano A, de Villemeur TB, Munnich A, Saudubray JM, Rabier D, Rigal O, Brivet M
     Comprehensive cDNA study and quantitative analysis of mutant HADHA and HADHB transcripts in a French cohort of 52 patients with mitochondrial trifunctional protein deficiency.
     Genet. Metab, 2011, 103, 341-348
126. Heron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, Caillaud C, Leade T, Chabrol B, Feillet F, Ogier H, Valayannapoulos V, Michelakalis H, Zafeiriou D, Lavery L, Wraith E, Danos O, Heard JM, Tardieu M. Incidence and natural history of mucopolysaccharisosis type III in France and comparison with United Kingdom and Greece.
     J. Med. Genet A, 2011, 155A, 58-68
127. Jacquemont S, Reymond A, Zufferey F, Harewood L, Walters RG, Kutalik Z, Martinet D, Shen Y, Valsesia A, Beckmann ND, Thorleifsson G, Belfiore M, Bouquillon S, Campion D, de Leeuw N, de Vries BBA, Esko T, Fernandez BA, Fernandez-Aranda F, Manuel Fernandez-Real J, Gratacos M, Guilmatre A, Hoyer J, Jarvelin M-R, Kooy RF, Kurg A, Le Caignec C, Maennik K, Platt OS, Sanlaville D, Van Haelst MM, Villatoro Gomez S, Walha F, Wu B-l, Yu Y, Aboura A, Addor M-C, Alembik Y, Antonarakis SE, Arveiler B, Barth M, Bednarek N, Bena F, Bergmann S, Beri M, Bernardini L, Blaumeiser B, Bonneau D, Bottani A, Boute O, Brunner HG, Cailley D, Callier P, Chiesa J, Chrast J, Coin L, Coutton C, Cuisset J-M, Cuvellier J-C, David A, de Freminville B, Delobel B, Delrue M-A, Demeer B, Descamps D, Didelot G, Dieterich K, Disciglio V, Doco-Fenzy M, Drunat S, Duban-Bedu B, Dubourg C, Moustafa JSE-S, Elliott P, Faas BHW, Faivre L, Faudet A, Fellmann F, Ferrarini A, Fisher R, Flori E, Forer L, Gaillard D, Gerard M, Gieger C, Gimelli S, Gimelli G, Grabe HJ, Guichet A, Guillin O, Hartikainen A-L, Heron D, Hippolyte L, Holder M, Homuth G, Isidor B, Jaillard S, Jaros Z, Jimenez-Murcia S, Helas GJ, Jonveaux P, Kaksonen S, Keren B, Kloss-Brandstaetter A, Knoers NVAM, Koolen DA, Kroisel PM, Kronenberg F, Labalme A, Landais E, Lapi E, Layet V, Legallic S, Leheup B, Leube B, Lewis S, Lucas J, MacDermot KD, Magnusson P, Marshall C, Mathieu-Dramard M, McCarthy MI, Meitinger T, Mencarelli MA, Merla G, Moerman A, Mooser V, Morice-Picard F, Mucciolo M, Nauck M, Ndiaye NC, Nordgren A, Pasquier L, Petit F, Pfundt R, Plessis G, Rajcan-Separovic E, Ramelli GP, Rauch A, Ravazzolo R, Reis A, Renieri A, Richart C, Ried JS, Rieubland C, Roberts W, Roetzer KM, Rooryck C, Rossi M, Saemundsen E, Satre V, Schurmann C, Sigurdsson E, Stavropoulos DJ, Stefansson H, Tengstrom C, Thorsteinsdottir U, Tinahones FJ, Touraine R, Vallee L, van Binsbergen E, Van der Aa N, Vincent-Delorme C, Visvikis-Siest S, Vollenweider P, Voelzke H, Vulto-van Silfhout AT, Waeber G, Wallgren-Pettersson C, Witwicki RM, Zwolinksi S, Andrieux J, Estivill X, Gusella JF, Gustafsson O, Metspalu A, Scherer SW, Stefansson K, Blakemore AIF, Beckmann JS and Froguel P.
     Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus.
     Nature, 2011, 478, 97-U111
128. Laroche D, Chollet-Martin S, Léturgie P, Malzac L, Phil M, Vergnaud MC, Neukirch C, Venemalm L, Guéant JL, Roland PN.
     In reply
     Anesthesiology, 2011, 115, 659-660
129. Maupetit-Mehouas S, Mariot V, Reynes C, Bertrand G, Feillet F, Carel JC, Simon D, Bihan H, Gajdos V, Devouge E, Shenoy S, Agbo-Kpati P, Ronan A, Naud-Saudreau C, Lienhardt A, Silve C, Linglart A.
     Quantification of the methylation at the GNAS locus identifies subtypes of sporadic pseudohyoparathyroidism type lb.
     Med. Genet., 2011, 48, 55-63
130. Sudour H, Schmitt C, Chastagner P, Feillet F.
     Acute hyperammoniemic encephalopathy complicating treatment with PEG-Asparaginase.
     J. Hematol., 2011, 86, 323-325
131. Awaga KL, Missihoun TD, Karou SD, Djadou KE, Chabi NW, Akati A, Lawson-Hukportie A, Amevo K, Djegno K, Guéant JL, Sanni A, Amouzou SK
     Genetic diversity and genotype multiplicity of plasmodium falciparum infections in symptomatic individuals in the maritime region of Togo.
     Med. Int. Health, 2012, 17, 153-160
132. Boutron A, Marabotti A, Facchiano A, Cheillan D, Zater M, Oliveira C, Costa C, Labrune P, Brivet M; French Galactosemia Working Group dont Feillet F
     Mutation spectrum in the French cohort of galactosemic patients and structural simulation of 27 novel missense variations
     Genet. Metab. 2012, 107, 438-447
133. Froguel P, Ndiaye NC, Bonnefond A, Bouatia-Naji N, Dechaume A, Siest G, Herbeth B, Falchi M, Bottolo L, Guéant-Rodriguez RM, Lecoeur C, Langlois MR, Labrune Y, Ruokonen A, El Shamieh S, Stathopoulou MG, Morandi A, Maffeis C, Meyre D, Delanghe JR, Jacobson P, Sjöström L, Carlsson LM, Walley A, Elliott P, Jarvelin MR, Dedoussis GV, Visvikis-Siest S.
     A genome-wide association study identifies rs2000999 as a strong genetic determinant of circulating haptoglobin levels.
     PLoS One, 2012, 7, :e32327
134. Galliot E, Laurent L, Hacquemand R, Pourié G, Millot JL.
     Fear-like behavioral responses in mice in different odorant environments: Trigeminal versus olfactory mediation under low doses.
     Processes, 2012, 90, 161-166
135. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA.
     First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study
     J.Clin. Pract., 2012, 66, 675-683
136. Leuret O, Barth M, Kuster A, Eyer D, de Parscau L, odent S, Gilbert-Dussardier B, Feillet F, Labarthe F
     Efficacy and safety of BH4 before the age of 4 years in patients with mild phenylketonuria.
     Inherit. Metab., 2012, 35, 975-981
137. MaCdonald A, van Rijn M, Feillet F, Lund AM, Bernstein L, Bosch AM, Gizewska M, van Spronsen FJ
     Adherence issues in inherited metabolic disorders treated by low natural protein diets
     Nutr. Metab., 2012, 61, 289-295
138. Schiff M, Broue P, Chabrol B, De Laet C, Habes D, Mention K, Sarles J, Spraul A, Valayannopoulos V, Ogier de Baulny H; French-Belgian study group for HT-1 don’t Feillet F
     Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines
     Inherit. Metab. Dis. 2012 35, 823-829
139. Stucki M*, Coelho D*, Suormala T, Burda P, Fowler B and Baumgartner MR.
     Molecular mechanisms leading to three different phenotypes in the cblD defect of intracellular cobalamin metabolism.
     Human Mol. Genet., 2012, 2, 1410-18 . *co-premiers auteurs
140. Teissier R, Nowak E, Assoun M, Mention K, Cano A, Fouilhoux A, Feillet F, Ogier H, Oger E, de Parscau L, AFDPHE.
     Maternal phenylketonuria : low phenylalaninemia might increase the risk of intra uterine growth retardation.
     Inherit. Metab., 2012, 35, 993-999
141. Ayuso P, Blanca-Lopez N, Dona I, Torres MJ, Guéant-Rodriguez RM, Canto G, Sanak M, Mayorga C, Guéant JL, Blanca M, Cornejo-Garcia JA
     Advances phentyping in hypersensitivity drug reactions to NSAIDs
     Exp. Allergy, 2013, 43, 1097-1109
142. Bourion-Bede S, Baumann C, Kermarrec S, Ligier F, Feillet F, Bonnemains C, et al
     Prognostic value of early therapeutic alliance in weight recovery : a prospective cohort of 108 adolescents with anorexia nervosa.
     The Journal of Adolescent Health : Official publication of the Society for Adolescent Medicine, 2013, 52, 344-350
143. Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, Edery P, Bottani A, Layet V, Caron O, Gilbert-Dussardier B, Delnatte C, Dugast C, Fricker JP, Bonneau D, Sevenet N, Longy M, Caux F; French Cowden Disease Network (dont Feillet F)
     High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome
     Med. Genet., 2013, 50, 255-263
144. Callier P, Aral B, Hanna N, Lambert S, Dindy H, Ragon C, Payet M, Collod-Beroud G, Carmignac V, Delrue MA, Goizet C, Philip N, Busa T, Dulac Y, Missotte I, Sznajer Y, Toutain A, Francannet C, Megarbane A, Julia S, Edouard T, Sarda P, Amiel J, Lyonnet S, Cormier-Daire V, Gilbert B, Jacquette A, Heron D, Collignon P, Lacombe D, Morice-Picard F, Jouk PS, Cusin V, Willems M, Sarrazin E, Amarof K, Coubes C, Addor MC, Journel H, Colin E, Khau Van Kien P, Baumann C, Leheup B,et al.
     Systematic molecular and cytogenetic screening of 100 patients with marfanoid syndromes and intellectual disability.
     Genet., 2013, 84, 507-521
145. Campo P, Ayuso P., Salas M; Plaza MC, Cornejo-Garcia JA, Dona I, Torres MJ, Blanca-Lopez N, Canto G, Guéant JL, Sanak M, Blanca M
     Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs.
     Allergy, 2013, 68, 1001-1007
146. Cang C, Zhou Y, Navarro B, Seo YJ, Aranda K, Shi L, Battaglia-Hsu S, Nissim I, Clapham DE, Ren D
     mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state.
     Cell, 2013, 152, 778-790
147. Cleary M, Trefz F, Muntau AC, Feillet F, van Spronsen FJ, Burlina A, Bélanger-Quintana A, Gizewska M, Gasteyger C, Bettiol E, Blau N, MacDonald A
     Fluctuations in phenylalanine concentrations in phenylketonuria : a review of possible relationship with outcomes.
     Genet Metab., 2013, 110, 418-423
148. Cornejo-Garcia JA, Liou LB, Blanca-Lopez N, Dona I, Chen CHU, Chou YC, Chuang HP, Wu JY, Chen YT, Plaza-Seron Mdel C, Mayorga C, Guéant-Rodriguez RM, Lin SC, Torres MJ, Campo P, Rondon C, Laguna JJ, Fernandez J, Guéant JL, Canto G, Blanca M, Lee MT
     Genome-wide association stdy in NSAID-induced acute urticaria/Angioedema in Spanish and Han Chinese populations.
     Pharmacogenomics, 2013, 14, 1857-1869
149. Dauber A, Golzio C, Guenot C, Jodelka FM, Kibaek M, Kjaergaard S, Leheup B, Martinet D, Nowaczyk MJ, Rosenfeld JA, Zeesman S, Zunich J, Beckmann JS, Hirschhorn JN, Hastings ML, Jacquemont S, Katsanis N.
     SCRIB and PUF60 are primary drivers of the multisystemic phenotypes of the 8q24.3 copy-number variant.
     J. Hum. Genet., 2013, 93, 798-811, Erratum in: Am J Hum Genet. 2013 Nov 7;93(5):994
150. Démurger F, Pasquier L, Dubourg C, Dupé V, Gicquel I, Evain C, Ratié L, Jaillard S, Beri M, Leheup B, Lespinasse J, Martin-Coignard D, Mercier S, Quelin C, Loget P, Marcorelles P, Laquerrière A, Bendavid C, Odent S, David V.
     Array-CGH Analysis Suggests Genetic Heterogeneity in Rhombencephalosynapsis.
     Syndromol., 2013, 4, 267-272
151. Emile JF, Tisserand J, Bergougnoux L, Nowak F, Faucher G, Surel S, Lamy A, Lecorre D, Helias-Rodzewicz Z, Hofman P, Sabourin JC, Laurent-Puig P; BRAF EQA Group (dont Jonveaux P).
     Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group.
     BMC Cancer, 2013, 13, 472
152. Imperiale A, Moussallieh FM, Sebag F, Brunaud L, Barlier A, Elbayed K, Bachellier P, Goichot B, Pacak K, Namer IJ, Taïeb D
     A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas
     PLoS One, 2013, 8, e80539
153. Keil S, Anjema K, vn Spronsen FJ, Lambruschini N, Burlina A, Bélanger-Quintana A, Couce Ml, Feillet F, Cerone R, Lotz-Havla AS, Muntau AC, Bosch AM, Meli CA, Billette de Villemueur T, Kern I, Riva E, Giovannini M, Damaj L, Leuzzi V, Blau N
     Long-term follow-up and outcome of phenylketonuria patients on sapropterin : a retrospective study.
     Pediatrics, 2013, 131, e1181-e1888
154. Kollen M, Mainard-Simard L, Journeau P, Leheup B, El-Rifaï R, Claudon M
     Mac Cune-Albright syndrome. Answer to the e-quid « Painful lameness in a child ».
     Interv. Imaging., 2013, 94, 474-478
155. Leroy C, Landais E, Briault S, David A, Tassy O, Gruchy N, Delobel B, Grégoire MJ, Leheup B, Taine L, Lacombe D, Delrue MA, Toutain A, Paubel A, Mugneret F, Thauvin-Robinet C, Arpin S, Le Caignec C, Jonveaux P, Beri M, Leporrier N, Motte J, Fiquet C, Brichet O, Mozelle-Nivoix M, Sabouraud P, Golovkine N, Bednarek N, Gaillard D, Doco-Fenzy M.
     The 2q37-deletion syndrome: an update of the clinical spectrum including overweight, brachydactyly and behavioural features in 14 new patients.
     J. Hum. Genet., 2013, 21, 602-612

156. Martinez E, Gérard N, Garcia MM, Mazur A, Guéant-Rodriguez RM, Comte B, Guéant JL, Brachet P.
     Myocardium proteome remodelling after nutritional deprivation of methyl donors.
     Nutr. Biochem., 2013, 24, 1241-1250
157. Mosca-Boidron AL, Valduga M, Thauvin-Robinet C, Lagarde N, Marle N, Henry C, Pinoit JM, Huet F, Beri-Deixheimer M, Ragon C, Gueeau L, Payet M, Callier P, Mugneret F, Jonveaux P, Faivre L.
     J. Med. Genet A, 2013, 161A, 1505-1507
158. Plaisancié J, Bailleul-Forestier I, Gaston V, Vaysse F, Lacombe D, Holder-Espinasse M, Abramowicz M, Coubes C, Plessis G, Faivre L, Demeer B, Vinccent-Delorme C, Dolldus H, Sigaudy S, Guillen-Navarro E, Verloes A, Jonveaux P, Martin-Coignard D, Colin E, Bieth E, Calvas P, Chassaing N.
     Mutations in WNT10A are frequently involved in oligodontia associated with minor signs of ectodermal dysplasia.
     J.Med. Genet. A, 2013, 161A, 671-678
159. Zufferey F, Hadj-Rabia S, De Sandre-Giovannoli A, Dufier JL, Leheup B, Schweitze C, Bodemer C, Cormier-Daire V, Le Merrer M.
     Acro-osteolysis, keloid like-lesions, distinctive facial features, and overgrowth: two newly recognized patients with premature aging syndrome, Penttinen type.
     J. Med. Genet. A., 2013, 161A, 1786-1791
160. Agopiantz M, Corbonnois P, Sorlin A, Bonnet C, Klein M, Hubert N, Pascal-Vigneron V, Jonveaux P, Cuny T, Leheup B, Weryha G.
     Endocrine disorders in Woodhouse-Sakati syndrome: a systematic review of the literature.
     Endocrinol. Invest., 2014, 37, 1-7
161. Barbare JC, Franco D, André T, Bronowicki JP, Merle P, Péron JM, Raoul JL, Seitz JF, Ychou M
     Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?
     Cancer, 2014, 101, 558-563
162. Bernstein LE, Helm JR, Rocha JC, Almedia MF, Feillet F, Link RM, Gizewska M
     Nutrition education tools used in phenylketonuria : clinician, parent and patient perspective from three international surveys.
     Hum. Nutr. Diet., 2014, 27, Suppl. 2, 4-11
163. Caumes R, Boespflug-Tanguy O, Villeneuve N, Lambert L, Delanoe C, Leheup B, Bahi-Buisson N, Auvin S.
     Late onset epileptic spasms is frequent in MECP2 gene duplication: electroclinical features and long-term follow-up of 8 epilepsy patients.
     J. Paediatr. Neurol., 2014, 18, 475-481
164. Cornejo-García JA, Flores C, Plaza-Serón MC, Acosta-Herrera M, Blanca-López N, Doña I, Torres MJ, Mayorga C, Guéant-Rodríguez RM, Ayuso P, Fernández J, Laguna JJ, Agúndez JA, García-Martín E, Guéant JL, Canto G, Blanca M
     Variants of CEP68 gene are associated with acute urticari/angioedema induced by multiple non-steroidal anti-inflammatory drugs.
     PLoS One, 2014, 9, e90966
165. Curie A, Nazir T, Brun A, Paulignan Y, Reboul A, Delange K, Cheylus A, Bertrand S, Rochefort F, Bussy G, Marignier S, Lacombe D, Chiron C, Cossée M, Leheup B, Philippe C, Laugel V, De Saint Martin A, Sacco S, Poirier K, Bienvenu T, Souville I, Gilbert-Dussardier B, Bieth E, Kauffmann D, Briot P, de Fréminville B, Prieur F, Till M, Rooryck-Thambo C, Mortemousque I, Bobillier-Chaumont I, Toutain A, Touraine R, Sanlaville D, Chelly J, Freeman S, Kong J, Hadjikhani N, Gollub RL, Roy A, des Portes V.
     The c.429_452 duplication of the ARX gene: a unique developmental-model of limb kinetic apraxia.
     Orphanet J. Rare Dis., 2014, 9, 25
166. Doco-Fenzy M, Leroy C, Schneider A, Petit F, Delrue MA, Andrieux J, Perrin-Sabourin L, Landais E, Aboura A, Puechberty J, Girard M, Tournaire M, Sanchez E, Rooryck C, Ameil A, Goossens M, Jonveaux P, Lefort G, Taine L, Cailley D, Gaillard D, Leheup B, Sarda P, Geneviève D
     Early-onset obesity and paternal 2pter deletion encompassing the ACP1, TMEM18, and MYT1L genes.
     Eur J. Hum. Genet., 2014, 22, 471-479
167. Duplomb L, Duvet S, Picot D, Jego G, El Chehadeh-Djebbar S, Marle N, Gigot N, Aral B, Carmignac V, Thevenon J, Lopez E, Rivière JB, Klein A, Philippe C, Droin N, Blair E, Girodon F, Donadieu J, Bellanné-Chantelot C, Delva L, Michalski JC, Solary E, Faivre L, Foulquier F, Thauvin-Robinet C.
     Cohen syndrome is associated with major glycosylation defects
     Mol. Genet., 2014, 23, 2391-2399
168. Fernandez TD, Mayorga C, Guéant JL, Blanca M, Cornejo-García JA
     Contributions of pharmacogenetics and transcriptomics to the understanding of the hypersensitivity drug reactions.
     Allergy, 2014, 69, 150-158
169. Harrison CJ, Rowley JD, Van den Berghe H, Bernheim A, Martineau M, Gautier M, Le Coniat-Busson M, Romana S, Dastugue N, Hagemeijer A, Jonveaux P, Nguyen-Khac F, Bernard OA.
     No chromosome arm unturned: in memory of Roland Berger 1934-2012.
     Leukemia, 2014, 28, 464-469: discussion 469
170. Kopajtich R, Nicholls TJ, Rorbach J, Metodiev MD, Freisinger P, Mandel H, Vanlander A, Ghezzi D, Carrozzo R, Taylor RW, Marquard K, Murayama K, Wieland T, Schwarzmayr T, Mayr JA, Pearce SF, Powell CA, Saada A, Ohtake A, Invernizzi F, Lamantea E, Sommerville EW, Pyle A, Chinnery PF, Crushell E, Okazaki Y, Kohda M, Kishita Y, Tokuzawa Y, Assouline Z, Rio M, Feillet F, Mousson de Camaret B, Chretien D, Munnich A, Menten B, Sante T, Smet J, Régal L, Lorber A, Khoury A, Zeviani M, Strom TM, Meitinger T, Bertini ES, Van Coster R, Klopstock T, Rötig A, Haack TB, Minczuk M, Prokisch H.
     Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathy
     J. Hum. Genet., 2014, 95, 708-20
171. Lacoste C, Leheup B, Agouti I, Mowat D, Giuliano F, Badens C
     Mutations of codon 2085 in the helicase domain of ATRX are recurrent and cause ATRX syndrome;
     Genet., 2014, 86, 502-503
172. Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ
     GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
     J. Clin. Pract., 2014, 68, 609-617
173. Mills PB, Camuzeaux SS, Footitt EJ, Mills KA, Gissen P, Fisher L, Das KB, Varadkar SM, Zuberi S, McWilliam R, Stödberg T, Plecko B, Baumgartner MR, Maier O, Calvert S, Riney K, Wolf NI, Livingston JH, Bala P, Morel CF, Feillet F, Raimondi F, Del Giudice E, Chong WK, Pitt M, Clayton PT
     Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome.
     Brain, 2014, 137, 1350-1360
174. Natiq A, Elalaoui SC, Miesch S, Bonnet C, Jonveaux P, Amzazi S, Sefiani A.
     A new case of de novo 19p13.2p13.12 deletion in a girl with overgrowth and severe developmental delay.
     Cytogenet. 2014, 7, 40
175. Perez M, Brunaud L, Kedaifa S, Guillotin C, Gerardin A, Quilliot D, Grosdidier G, Reibel N.
     Does Anatomy Explain the Origin of a Leak after Sleeve Gastrectomy?
     Surg., 2014, 24, 1717-1723
176. Petit JM, Hamza S, Rollot F, Sigonney V, Crevisy E, Duvillard L, Raab JJ, Bronowicki JP, Bernard-Chabert B, Di Martino V, Doffoel M, Barraud H, Richou C, Jouve JL, Hillon P
     Impact of liver disease severity and etiology on the occurrence of diabetes mellitus in patients with liver cirrhosis.
     Acta Diabetol., 2014, 51, 455-460
177. Piccand J, Meunier A, Merle C, Jia Z, Barnier JV, Gradwohi G
     Pak3 pormotes cell cycle exit and differenciation of b-cells in the embryonic pancreas and is necessary to maintain glucose homeostasis in adult mice.
     Diabetes, 2014, 63, 203-215
178. Youcef G, Olivier A, L’Huillier CP, Labat C, Fay R, Tabcheh L, Toupance S, Rodriguez-Guéant RM, Bergerot D, Jaisser F, Lacolley P, Zannad F, Laurent Vallar, Pizard A
     Simultaneous characterization of metabolic, cardiac, vascular and renal phenotypes of lean and obese SHHF rats
     PLoS One, 2014, 9, e96452

179. Antony-Debré I, Manchev VT, Balayn N, Bluteau D, Tomowiak C, Legrand C, Langlois T, Bawa O, Tosca L, Tachdjian G, Leheup B, Debili N, Plo I, Mills JA, French DL, Weiss MJ, Solary E, Favier R, Vainchenker W, Raslova H
     Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia
     Blood. 2015, 125, 930-40
180. Bursztejn AC, Briggs TA, Del Toro Duany Y, Anderson BH, O’Sullivan J, Williams SG, Bodemer C, Fraitag S, Gebhard F, Leheup B, Lemelle I, Oojageer A, Raffo E, Schmitt E, Rice GI, Hur S, Crow YJ
     Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes
     J. Dermatol., 2015, 173, 1505-1513
181. Chatron N, Haddad V, Andrieux J, Désir J, Boute O, Dieux A, Baumann C, Drunat S, Gérard M, Bonnet C, Leheup B, Till M, Rossi M, Flori E, Alembik Y, Stewart H, McParland J, Bernardini L, Castelluccio P, Roos L, Tümer Z, Fagan K, Hackett A, Bain N, van Haeringen A, Ruivenkamp C, Benzacken B, Sanlaville D, Edery P, Aboura A, Schluth-Bolard C
     Refinement of genotype-phenotype correlation in 18 patients carrying a 1q24q25 deletion
     .J Med. Genet. A., 2015, 167, 1008-1017
182. El Chehadeh S, Bonnet C, Callier P, Béri M, Dupré T, Payet M, Ragon C, Mosca-Boidron AL, Marle N, Mugneret F, Masurel-Paulet A, Thevenon J, Seta N, Duplomb L, Jonveaux P, Faivre L, Thauvin-Robinet C
     Homozygous Truncating Intragenic Duplication in TUSC3 Responsible for Rare Autosomal Recessive Nonsyndromic Intellectual Disability with No Clinical or Biochemical Metabolic Markers
     JIMD Rep., 2015, 20, 45-55
183. Fantola G, Nguyen-Thi PL, Reibel N, Sirveaux MA, Germain A, Ayav A, Bresler L, Zarnegar R, (dont Brunaud L)
     Risk Factors for Postoperative Morbidity After Totally Robotic Gastric Bypass in 302 Consecutive Patients
     Surg., 2015, 25, 1229-1238
184. Guissart C, Li X, Leheup B, Drouot N, Montaut-Verient B, Raffo E, Jonveaux P, Roux AF, Claustres M, Fliegel L, Koenig M
     Mutation of SLC9A1, encoding the major Na⁺/H⁺ exchanger, causes ataxia-deafness Lichtenstein-Knorr syndrome
     Mol; Genet., 2015, 24, 463-70
185. Imperiale A, Moussallieh FM, Roche P, Battini S, Cicek AE, Sebag F, Brunaud L, Barlier A, Elbayed K, Loundou A, Bachellier P, Goichot B, Stratakis CA, Pacak K, Namer IJ, Taïeb D
     Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
     Neoplasia, 2015, 17, 55-65
186. Perez M, Brunaud L, Kedaifa S, Guillotin C, Gerardin A, Quilliot D, Grosdidier G, Reibel N
     Does anatomy explain the origin of a leak after sleeve gastrectomy? Comments & answers
     Obes Surg, 2015, 25, 715-716
187. Pochon C, Oger E, Michel G, Dalle JH, Salmon A, Nelken B, Bertrand Y, Cavé H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Méchinaud F, Rohrlich P, Paillard C, Demeocq F, Schneider P, Plantaz D, Poirée M, Eliaou JF, Semana G, Drunat S, Jonveaux P, Bordigoni P, Gandemer V
     Follow-up of post-transplant minimal residual disease and chimerism in childhood lymphoblastic leukaemia: 90 d to react
     J. Haematol., 2015, 169, 249-261
188. Valduga M, Philippe C, Lambert L, Bach-Segura P, Schmitt E, Masutti JP, François B, Pinaud P, Vibert M, Jonveaux P
     WWOX and severe autosomal recessive epileptic encephalopathy: first case in the prenatal period
     Hum. Genet., 2015, 60, 267-271
189. Fantola G, Reibel N, Germain A, Ayav A, Bresler L, Brunaud L
     Second-stage robot-assisted biliopancreatic diversion with duodenal switch after sleeve gastrectomy
     Surg., 2015, 25, 197-198

190. Trefz FK, van Spronsen FJ, MacDonald A, Feillet F, Muntau AC, Belanger-Quintana A, Burlina A, Demirkol M, Giovannini M, Gasteyger C.
     Management of adult patients with phenylketonuria: survey results from 24 countries
     J. Pediatr., 2015, 174, 119-127

191. Danecka MK, Woidy M, Zschocke J, Feillet F, Muntau AC, Gersting SW
     Mapping the functional landscape of frequent phenylalanine hydroxylase (PAH) genotypes promotes personalised medicine in phenylketonuria
     Med. Genet., 2015, 52, 175-185

192. Lebigot E, Brassier A, Zater M, Imanci D, Feillet F, Thérond P, de Lonlay P, Boutron A
     Fructose 1,6-bisphosphatase deficiency: clinical, biochemical and genetic features in French patients
     Inherit. Metab. Dis., 2015, 38, 881-887

193. Trefz F, Lichtenberger O, Blau N, Muntau AC, Feillet F, Bélanger-Quintana A, van Spronsen F, Munafo A
     Tetrahydrobiopterin (BH4) responsiveness in neonates with hyperphenylalaninemia: a semi-mechanistically-based, nonlinear mixed-effect modeling
     Genet. Metab., 2015, 114, 564-9

194. Trefz FK, Muntau AC, Lagler FB, Moreau F, Alm J, Burlina A, Rutsch F, Bélanger-Quintana A, Feillet F; KAMPER investigators
     The Kuvan® Adult Maternal Paediatric European Registry (KAMPER) Multinational Observational Study: Baseline and 1-Year Data in Phenylketonuria Patients Responsive to Sapropterin
     JIMD Rep., 2015, 23, 35-43

195. Guffon N, Heron B, Chabrol B, Feillet F, Montauban V, Valayannopoulos V
     Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study
     Orphanet J. Rare Dis., 2015, 10, 43

196. Sicre de Fontbrune F, Moignet A, Beaupain B, Suarez F, Galicier L, Socié G, Varet B, Coppo P, Michel M, Pautas C, Oksenhendler E, Lengline E, Terriou L, Moreau P, Chantepie S, Casadevall N, Michot JM, Gardembas M, Michallet M, Croisille L, Audrain M, Bellanné-Chantelot C, Donadieu J, Lamy T; French Severe Chronic Neutropenia Registry (dont F. Feillet)
     Severe chronic primary neutropenia in adults: report on a series of 108 patients
     Blood, 2015, 126, 1643-1650

197. Burton BK, Balwani M, Feillet F, Barić I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG
     A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency
     Engl. J. Med., 2015, 373, 1010-1020

198. MacDonald A, Ahring K, Almeida MF, Belanger-Quintana A, Blau N, Burlina A, Cleary M, Coskum T, Dokoupil K, Evans S, Feillet F, Giżewska M, Gokmen Ozel H, Lotz-Havla AS, Kamieńska E, Maillot F, Lammardo AM, Muntau AC, Puchwein-Schwepcke A, Robert M, Rocha JC, Santra S, Skeath R, Strączek K, Trefz FK, van Dam E, van Rijn M, van Spronsen F, Vijay S
     The challenges of managing coexistent disorders with phenylketonuria: 30 cases
     Genet. Metab., 2015, 116, 242-251

199. Paulsson JO, Svahn F, Welander J, Brunaud L, Söderkvist P, Gimm O, Stenman A, Juhlin CC
     Absence of the BRAF V600E mutation in pheochromocytoma
     Invest., 2015 Dec 28.
     

200. Landais E, Leroy C, Kleinfinger P, Brunet S, Koubi V, Pietrement C, Poli-Mérol ML, Fiquet C, Souchon PF, Beri M, Jonveaux P, Garnotel R, Gaillard D, Doco-Fenzy M
     A pure familial 6q15q21 split duplication associated with obesity and transmitted with partial reduction
     J. Med. Genet. A, 2015, 167, 1275-1284
201. Baert-Desurmont S, Charbonnier F, Houivet E, Ippolito L, Mauillon J, Bougeard M, Abadie C, Malka D, Duffour J, Desseigne F, Colas C, Pujol P, Lejeune S, Dugast C, Buecher B, Faivre L, Leroux D, Gesta P, Coupier I, Guimbaud R, Berthet P, Manouvrier S, Cauchin E, Prieur F, Laurent-Puig P, Lebrun M, Jonveaux P, Chiesa J, Caron O, Morin-Meschin ME, Polycarpe-Osaer F, Giraud S, Zaanan A, Bonnet D, Mansuy L, Bonadona V, El Chehadeh S, Duhoux F, Gauthier-Villars M, Saurin JC, Collonge-Rame MA, Brugières L, Wang Q, Bressac-de Paillerets B, Rey JM, Toulas C, Buisine MP, Bronner M, Sokolowska J, Hardouin A, Cailleux AF, Sebaoui H, Blot J, Tinat J, Benichou J, Frebourg T
     Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk
     J. Hum. Genet., 2016, 24, 99-105
202. Cessans C, Ehlinger V, Arnaud C, Yart A, Capri Y, Barat P, Cammas B, Lacombe D, Coutant R, David A, Baron S, Weill J, Leheup B, Nicolino M, Salles JP, Verloes A, Tauber M, Cavé H, Edouard T
     Growth patterns of patients with Noonan syndrome: correlation with age and genotype
     J. Endocrinol., 2016;174, 641-50
203. Croisé P, Houy S, Gand M, Lanoix J, Calco V, Tóth P, Brunaud L, Lomazzi S, Paramithiotis E, Chelsky D, Ory S, Gasman S
     Cdc42 and Rac1 activity is reduced in human pheochromocytoma and correlates with FARP1 and ARHGEF1 expression
     Relat. Cancer, 2016, 23, 281-293
204. El Chehadeh S, Faivre L, Mosca-Boidron AL, Malan V, Amiel J, Nizon M, Touraine R, Prieur F, Pasquier L, Callier P, Lefebvre M, Marle N, Dubourg C, Julia S, Sarret C, Francannet C, Laffargue F, Boespflug-Tanguy O, David A, Isidor B, Le Caignec C, Vigneron J, Leheup B, Lambert L, Philippe C, Cuisset JM, Andrieux J, Plessis G, Toutain A, Goldenberg A, Cormier-Daire V, Rio M, Bonnefont JP, Thevenon J, Echenne B, Journel H, Afenjar A, Burglen L, Bienvenu T, Addor MC, Lebon S, Martinet D, Baumann C, Perrin L, Drunat S, Jouk PS, Devillard F, Coutton C, Lacombe D, Delrue MA, Philip N, Moncla A, Badens C, Perreton N, Masurel A, Thauvin-Robinet C, Portes VD, Guibaud L
     Large national series of patients with Xq28 duplication involving MECP2: Delineation of brain MRI abnormalities in 30 affected patients
     J. Med. Genet. A, 2016, 170, 116-129
205. Froese DS, Huemer M, Suormala T, Burda P, Coelho D, Guéant JL, Landolt MA, Kožich V, Fowler B, Baumgartner MR
     Mutation Update and Review of Severe MTHFR Deficiency
     Mutat., 2016, 37, 427-438
206. Giżewska M, MacDonald A, Bélanger-Quintana A, Burlina A, Cleary M, Coşkun T, Feillet F, Muntau AC, Trefz FK, van Spronsen FJ, Blau N
     Diagnostic and management practices for phenylketonuria in 19 countries of the South and Eastern European Region: survey results
     J. Pediatr., 2016, 175, 261-272
207. Guissart C, Drouot N, Oncel I, Leheup B, Gershoni-Barush R, Muller J, Ferdinandusse S, Larrieu L, Anheim M, Arslan EA, Claustres M, Tranchant C, Topaloglu H, Koenig M
     Genes for spinocerebellar ataxia with blindness and deafness (SCABD/SCAR3, MIM# 271250 and SCABD2).
     J. Hum. Genet., 2016, 24, 1154-1159
208. Latger-Cannard V, Philippe C, Bouquet A, Baccini V, Alessi MC, Ankri A, Bauters A, Bayart S, Cornillet-Lefebvre P, Daliphard S, Mozziconacci MJ, Renneville A, Ballerini P, Leverger G, Sobol H, Jonveaux P, Preudhomme C, Nurden P, Lecompte T, Favier R
     Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders
     Orphanet J. Rare Dis., 2016, 11, 49
209. Lefebvre M, Sanlaville D, Marle N, Thauvin-Robinet C, Gautier E, El Chehadeh S, Mosca-Boidron AL, Thevenon J, Edery P, Alex-Cordier MP, Till M, Lyonnet S, Cormier-Daire V, Amiel J, Philippe A, Romana S, Malan V, Afenjar A, Marlin S, Chantot-Bastaraud S, Bitoun P, Heron B, Piparas E, Morice-Picard F, Moutton S, Chassaing N, Vigouroux-Castera A, Lespinasse J, Manouvrier-Hanu S, Boute-Benejean O, Vincent-Delorme C, Petit F, Le Meur N, Marti-Dramard M, Guerrot AM, Goldenberg A, Redon S, Ferrec C, Odent S, Le Caignec C, Mercier S, Gilbert-Dussardier B, Toutain A, Arpin S, Blesson S, Mortemousque I, Schaefer E, Martin D, Philip N, Sigaudy S, Busa T, Missirian C, Giuliano F, Benailly HK, Van Kien PK, Leheup B, Benneteau C, Lambert L, Caumes R, Kuentz P, François I, Heron D, Keren B, Cretin E, Callier P, Julia S, Faivre L
     Genetic counselling difficulties and ethical implications of incidental findings from array-CGH: A 7-year national survey
     Genet., 2016, 89, 630-635
210. Prasad MK, Geoffroy V, Vicaire S, Jost B, Dumas M, Le Gras S, Switala M, Gasse B, Laugel-Haushalter V, Paschaki M, Leheup B, Droz D, Dalstein A, Loing A, Grollemund B, Muller-Bolla M, Lopez-Cazaux S, Minoux M, Jung S, Obry F, Vogt V, Davideau JL, Davit-Beal T, Kaiser AS, Moog U, Richard B, Morrier JJ, Duprez JP, Odent S, Bailleul-Forestier I, Rousset MM, Merametdijan L, Toutain A, Joseph C, Giuliano F, Dahlet JC, Courval A, El Alloussi M, Laouina S, Soskin S, Guffon N, Dieux A, Doray B, Feierabend S, Ginglinger E, Fournier B, de la Dure Molla M, Alembik Y, Tardieu C, Clauss F, Berdal A, Stoetzel C, Manière MC, Dollfus H, Bloch-Zupan A
     A targeted next-generation sequencing assay for the molecular diagnosis of genetic disorders with orodental involvement
     Med. Genet., 2016, 53, 98-110
211. Roucher-Boulez F, Mallet-Moták D, Samara-Boustani D, Jilani H, Asmahane L, Souchon PF, Simon D, Nivot S, Heinrichs C, Ronze M, Bertagna X, Groisne L, Leheup B, Catherine NS, Blondin G, Lefevre C, Lemarchand L, Morel Y
     NNT mutations: a cause of primary adrenal insufficiency, oxidative stress and extra-adrenal defects
     J. Endocrinol., 2016, 175, 73-84
212. Saunier C, Støve SI, Popp B, Gérard B, Blenski M, AhMew N, de Bie C, Goldenberg P, Isidor B, Keren B, Leheup B, Lampert L, Mignot C, Tezcan K, Mancini GM, Nava C, Wasserstein M, Bruel AL, Thevenon J, Masurel A, Duffourd Y, Kuentz P, Huet F, Rivière JB, van Slegtenhorst M, Faivre L, Piton A, Reis A, Arnesen T, Thauvin-Robinet C, Zweier C
     Expanding the Phenotype Associated with NAA10 Related N-terminal Acetylation Deficiency
     Mutat., 2016, 37, 755-764
213. Sinilnikova OM, Dondon MG, Eon-Marchais S, Damiola F, Barjhoux L, Marcou M, Verny-Pierre C, Sornin V, Toulemonde L, Beauvallet J, Le Gal D, Mebirouk N, Belotti M, Caron O, Gauthier-Villars M, Coupier I, Buecher B, Lortholary A, Dugast C, Gesta P, Fricker JP, Noguès C, Faivre L, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard CM, Pujol P, Lasset C, Longy M, Bignon YJ, Adenis C, Venat-Bouvet L, Demange L, Dreyfus H, Frenay M, Gladieff L, Mortemousque I, Audebert-Bellanger S, Soubrier F, Giraud S, Lejeune-Dumoulin S, Chevrier A, Limacher JM, Chiesa J, Fajac A, Floquet A, Eisinger F, Tinat J, Colas C, Fert-Ferrer S, Penet C, Frebourg T, Collonge-Rame MA, Barouk-Simonet E, Layet V, Leroux D, Cohen-Haguenauer O, Prieur F, Mouret-Fourme E, Cornélis F, Jonveaux P, Bera O, Cavaciuti E, Tardivon A, Lesueur F, Mazoyer S, Stoppa-Lyonnet D, Andrieu N
     GENESIS: a French national resource to study the missing heritability of breast cancer
     BMC Cancer, 2016 Jan 12, doi: 10.1186/s12885-015-2028-9
214. Sobrier ML, Tsai YC, Pérez C, Leheup B, Bouceba T, Duquesnoy P, Copin B, Sizova D, Penzo A, Stanger BZ, Cooke NE, Liebhaber SA, Amselem S
     Functional characterization of a human POU1F1 mutation associated with isolated growth hormone deficiency: a novel etiology for IGHD
     Mol. Genet., 2016, 25, 472-483
215. Stenman A, Welander J, Gustavsson I, Brunaud L, Bäckdahl M, Söderkvist P, Gimm O, Juhlin CC, Larsson C.
     HRAS mutation prevalence and associated expression patterns in pheochromocytoma
     Genes Chromosomes Cancer, 2016, 55, :452-459
216. Thevenon J, Duffourd Y, Masurel-Paulet A, Lefebvre M, Feillet F, El Chehadeh-Djebbar S, St-Onge J, Steinmetz A, Huet F, Chouchane M, Darmency-Stamboul V, Callier P, Thauvin-Robinet C, Faivre L, Rivière JB
     Diagnostic odyssey in severe neurodevelopmental disorders: Towards clinical whole-exome sequencing as a first-line diagnostic test
     Genet., 2016, 89, 700-707
217. Urbanet R, Cat AND, Feraco A, Venteclef N, El Mogrhabi S, Sierra-Ramos C, Alvarez de la Rosa D, Adler GK, Quilliot D, Rossignol P, Fallo F, Touyz RM and Jaisser F. Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. Hypertension, 2015, 66, 149-157.
218. Vincent M, Geneviève D, Ostertag A, Marlin S, Lacombe D, Martin-Coignard D, Coubes C, David A, Lyonnet S, Vilain C, Dieux-Coeslier A, Manouvrier S, Isidor B, Jacquemont ML, Julia S, Layet V, Naudion S, Odent S, Pasquier L, Pelras S, Philip N, Pierquin G, Prieur F, Aboussair N, Attie-Bitach T, Baujat G, Blanchet P, Blanchet C, Dollfus H, Doray B, Schaefer E, Edery P, Giuliano F, Goldenberg A, Goizet C, Guichet A, Herlin C, Lambert L, Leheup B, Martinovic J, Mercier S, Mignot C, Moutard ML, Perez MJ, Pinson L, Puechberty J, Willems M, Randrianaivo H, Szaskon K, Toutain A, Verloes A, Vigneron J, Sanchez E, Sarda P, Laplanche JL, Collet C.
     Treacher Collins syndrome: a clinical and molecular study based on a large series of patients
     Med., 2016, 18, 49-56
219. Wintjens R, Bozon D, Belabbas K, MBou F, Girardet JP, Tounian P, Jolly M, Boccara F, Cohen A, Karsenty A, Dubern B, Carel JC, Azar-Kolakez A, Feillet F, Labarthe F, Gorsky AM, Horovitz A, Tamarindi C, Kieffer P, Lienhardt A, Lascols O, Di Filippo M, Dufernez F
     Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.
     Lipid. Res., 2016, 57, 482-491
220. Youcef G, Olivier A, Nicot N, Muller A, Deng C, Labat C, Fay R, Rodriguez-Guéant RM, Leroy C, Jaisser F, Zannad F, Lacolley P, Vallar L, Pizard A
     Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats
     J. Pharmacol., 2016, 173, 1805-1819
221. Younossi ZM, Stepanova M, Pol S, Bronowicki J-P, Carrieri MP and Bourliere M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
     Liver International., 2016, 36, 42-48.

222. Chevaliez S, Hézode C, Soulier A, Costes B, Buvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-eddine M, Babany G, Pawlotsky JM.
     High-dose pegylated interferon-a and ribavirin in nonresponder hepatitis C patients and relationship with Il-28B genotype (SYREN Trial).
     Gastroenterology, 2011, 141, 119-127
223. Foster GR, Hézode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M
     Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections
     Gastroenterology, 2011, 141, 881-889.e1
224. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G.
     A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C
     Gastroenterology, 2011, 141, 890-899. e1-4
225. Laroche D, Chollet-Martin S, Leturgie P, Malzac L, Vergnaud MC, Neukirch C, Venemalm L, Gueant JL, Roland PN
     Evaluation of a new routine diagnostic tes for immunoglobulin E sensitization to neuromuscular blocking agents;
     Anesthesiology, 2011, 114, 91-97
226. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P, Ollivier I, Vinel JP, Mathurin P, Bronowicki JP, Vilgrain V, N’Kontchou G, Beaugrand M, Chevret S; Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH).
     Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities
     Hepatology, 2011, 54, 1987-1997
227. Zeuzem S, Asselah T, Angus P , arski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, bronowicki JP, Roberts S, Arasteh K, Zoulim, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO.
     Efficacy of the proetease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
     Gastroenterology, 2011, 141, 2047-2055

228. Bourcier V, Winnock M, Ait Ahmed M, Sogni P, Pambrun E, Poizot-Martin I, Chaffaut C, Chevret S, Trinchet JC, Salmon D; ANRS CO13 Hepavih study group; ANRS CO12 Cirvir study group (don’t Bronowicki JP)
     Primary liver cancer is more aggressive in HIV-HCV coinfection than in HCV infection. A prospective study (ANRS CO13 Hepavih and CO12 Cirvir).
     Res. Hepatol. Gastroenterol., 2012, 36, 214-221
229. Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, Calès P; multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies (dont Bronowicki JP)
     Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive
     Hepatology, 2012, 55, 58-67
230. Leroy V, Serfaty L, Bourlière M, Bronowicki JP, Delasalle P, Pariente A, Pol S, Zoulim F, Pageaux GP, French association for the study of the liver
     Protease inihibitor-based triple therapy in chronic hepatitis C : guidelines by the French Association for the Study of the Liver
     Live Int., 2012, 32, 1477-1492
231. Martinez SM, Foucher J, Combis JM, Metivier S, Brunetto M, Capron D, Bourlière M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, dde Lédinghen V
     Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy.
     Plos One, 2012, 7, e47715
232. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hézode C, Lim JK, Bronowicki JP, Abrams GA, Bräu N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S
     Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
     Lancet Infect. Dis., 2012, 12, 671-677
233. Poordad F, bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR, SPRINT-2 Trial Investigators
     Factors that predict response of patients with hepatitis C virus infction to boceprevir.
     Gastroenterology, 2012, 143, 608-18.e1-5
234. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M; ANRS HCEP 23 Fibrostar Group
     Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study
     Hepatol., 2012, 56, 55-62

235. Bosselut N, Taibi L, Guéchot J, Zarski JP, Sturm N, Gelineau MC, Poggi B, Thoret S, Lasnier E, Baudin B, Housset C, Vaubourdolle M; ANRS HCEP 23 Fibrostar Group (dont Bronowicki JP)
     Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.
     Chim. Acta., 2013, 415, 63-68
236. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, Fouchard-Hubert I, Gallois Y, Oberti F, Bertrais S, Calès P; Multicentric Group from ANRS/HC/EP23 FIBROSTAR Studies
     Determination of reliability criteria for liver stiffness evaluation by transient elastography
     Hepatology, 2013, 57, 1182-1191
237. Buron G, Hacquemand R, Pourié G, Jacquot L, Brand G.
     Effects of pyridine inhalation exposure on olfactory epithelium in mice.
     Exp Toxicol Pathol., 2013, 65, 159-64
238. Couzigou P, Pérusat S, Bourlière M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chêne G; ANRS HC16 GAMMATRI Trial Group
     Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
     Gastroenterol. Hepatol., 2013, 28, 329-334
239. Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH
     Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study
     BMC Infect. Dis., 2013, 13, 190
240. Gordon SC, Yoshida EM, Lawitz EJ, Bacon BR, Sulkowski MS, Davis M, Poordad F, Bronowicki JP, Esteban R, Sniukiene V, Burroughs MH, Deng W, Dutko FJ, Brass CA, Albrecht JK, Rajender Reddy K.
     Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin
     Pharmacol. Ther., 2013, 38, 16-27
241. Hristova L, Soyer P, Hoeffel C, Marteau P, Oussalah A, Lavergne-Slove A, Boudiaf M, Dohan A, Laurent V.
     Colorectal cancer in inflammatory bowel diseases: CT features with pathological correlation.
     Imaging, 2013, 38, 421-435
242. Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group
     Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C
     Agents Chemother., 2013, 57, 4727-4735
243. Müller G, Saint F, Hamy A, Lifante JC, Carnaille B, Sebag F, Ménégaux F, Vandwalle J, Drui D, Caillard C, Rodien P, Roy M, Peix JL, Pattou F, Brunaud L, Henry JF, Mirallié E
     Pheochromocytoma revealed by acute heart failure. When should we operate? Presented at the ESES Congress, Gothenburg May 25-26, 2012.4
     Langenbecks Arch. , 2013, 398, 729-733
244. Perrenot C, Germain A, Scherrer ML, Ayav A, Brunaud L, Bresler L
     Long-term outcomes of robot-assisted laparoscopic rectopexy for rectal prolapse
     Colon. Rectum, 2013, 56, 909-914
245. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators (dont Bronowicki JP)
     Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection–a randomized trial
     Gastroenterology, 2013, 145, 1035-1044.e5
246. Sulkowski MS, Bourlière M, Bronowicki JP, Asselah T, Pawlotsky JM, Shafran SD, Pol S, Mauss S, Larrey D, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO
     Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
     Hepatology, 2013, 57, 2155-2163
247. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM , SPRINT-2 Trial Investigators
     Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial
     Hepatology, 2013, 57, 974-984
248. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Böcher WO, Mensa FJ
     Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results
     Ther., 2013, 18, 1015-1019
249. Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchlmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ
     Faldaprevir and deleobuvir for HCV genotype 1 infection.
     Engl. J. Med., 2013, 369, 639-639

250. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators dont Bronowicki JP
     Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
     Engl. J. Med., 2014, 370, 1889-1898
251. Ariza A, Barrionuevo E, Mayorga C, Montañez MI, Perez-Inestrosa E, Ruiz-Sánchez A, Rodríguez-Guéant RM, Fernández TD, Guéant JL, Torres MJ, Blanca M
     IgE to penicillins with different specificites can be identified by a multiepitope macromolecule : bihaptenic penicillin structures and IgE specficities;
     Immunol. Methods, 2014, 406, 43-50
252. Boursier J, de Ledinghen V, Sturm N, Amrani L, Bacq Y, Sandrini J, Le Bail B, Chaigneau J, Zarski JP, Gallois Y, Leroy V, Al Hamany Z, Oberti F, Fouchard-Hubert I, Dib N, Bertrais S, Rousselet MC, Calès P; Multicentre group ANRS HC EP23 FIBROSTAR (dont Bronwicki JP)
     Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C
     Gastroenterol., 2014, 49, 527-537
253. Calès P, Boursier J, Ducancelle A, Oberti F, Hubert I, Hunault G, de Lédinghen V, Zarski JP, Salmon D, Lunel F; ANRS HC EP 23 Fibrostar Study dont Bronowicki JP
     Improved fibrosis staging by elastometry and blood test in chronic hepatitis C.
     Liver Int., 2014, 34, 907-917
254. Degrolard-Courcet, E., J. Sokolowska, M.M. Padeano, S. Guiu, M. Bronner, C. Chery, F. Coron, C. Lepage, C. Chapusot, C. Loustalot, J.L. Jouve, C. Hatem, E. Ferrant, L. Martin, C. Coutant, A. Baurand, G. Couillault, A. Delignette, S. El Chehadeh, S. Lizard, L. Arnould, P. Fumoleau, P. Callier, F. Mugneret, C. Philippe, T. Frebourg, P. Jonveaux, and L. Faivre.
     Development of primary early-onset colorectal cancers due to biallelic mutations of the FANCD1/BRCA2 gene.
     J. Hum. Genet., 2014, 22, 979-87
255. Duvillard L, Ortega-Deballon P, Bourredjem A, Scherrer ML, Mantion G, Delhorme JB, Deguelte-Lardière S, Petit JM, Bonithon-Kopp C; AGARIC study group ( dont Brunaud L)
     A case-control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer
     BMC Cancer. 2014 Dec 3, 14:912
256. Fantola G, Perrenot C, Germain A, Ayav A, Brunaud L, Bresler L
     Simulator practice is not enough to become a robotic surgeon: the driving lessons model
     J Laparoendosc Adv Surg Tech A, 2014, 24, 260
257. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M
     Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial
     Gastroenterology, 2014, 146, 1669-1679
258. Fouquet T, Germain A, Brunaud L, Bresler L, Ayav A
     Is perineural invasion more accurate than other factors to predict early recurrence after pancreatoduodenectomy for pancreatic head adenocarcinoma?
     World J. Surg., 2014, 38, 2132-2137
259. Frisoni R, Germain A, Ayav A, Brunaud L, Bresler L
     Thoracoscopic treatment of a right Bochdalek hernia in an adult (with video)
     Visc. Surg., 2014, 151, 239
260. Germain A, Perrenot C, Scherrer ML, Ayav C, Brunaud L, Ayav A, Bresler L.
     Long-term outcome of robotic-assisted laparoscopic rectopexy for full-thickness rectal prolapse in elderly patients
     Colorectal Dis., 2014,16, 198-202
261. Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ
     Boceprevir plus peginterferon alpha-2b/ribavirin in chronic hepatitis C genotype 1 : impact of baseline viral load on sustained virologic response.
     Clin. Gastroenterol., 2014, 48, 435-443
262. Gronnier C, Tréchot B, Duhamel A, Mabrut JY, Bail JP, Carrere N, Lefevre JH, Brigand C, Vaillant JC, Adham M, Msika S, Demartines N, El Nakadi I, Piessen G, Meunier B, Collet D, Mariette C; FREGAT Working Group-FRENCH-AFC, Luc G, Cabau M, Jougon J, Badic B, Lozach P, Cappeliez S, Lebreton G, Alves A, Flamein R, Pezet D, Pipitone F, Iuga BS, Contival N, Pappalardo E, Mantziari S, Hec F, Vanderbeken M, Tessier W, Briez N, Fredon F, Gainant A, Mathonnet M, Bigourdan JM, Mezoughi S, Ducerf C, Baulieux J, Pasquer A, Baraket O, Poncet G, Vaudoyer D, Enfer J, Villeneuve L, Glehen O, Coste T, Fabre JM, Marchal F, Frisoni R, Ayav A, Brunaud L, Bresler L, Cohen C, Aze O, Venissac N, Pop D, Mouroux J, Donici I, Prudhomme M, Felli E, Lisunfui S, Seman M, Petit GG, Karoui M, Tresallet C, Ménégaux F, Hannoun L, Malgras B, Lantuas D, Pautrat K, Pocard M, Valleur P
     Impact of neoadjuvant chemoradiotherapy on postoperative outcomes after esophageal cancer resection: results of a European multicenter study
     Surg., 2014, 260, 764-770; discussion 770-1
263. Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group
     Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
     Gastroenterology, 2014, 147, 132-142
264. Huguet S, Leheup B, Aslan M, Muller F, Dautel G, Journeau P; French Society of Pediatric Orthopaedics (SOFOP).
     Radiological and clinical analysis of Madelung’s deformity in children
     Traumatol. Surg. Res., 2014, 100(6 Suppl):S349-S352
265. Kleiman DA, Beninato T, Bosworth BP, Brunaud L, Ciecierega T, Crawford CV Jr, Turner BG, Fahey TJ 3rd, Zarnegar R
     Early referral for esophageal pH monitoring is more cost-effective than prolonged empiric trials of proton-pump inhibitors for suspected gastroesophageal reflux disease
     Gastrointest. Surg., 2014, 18, 26-33; discussion 33-4
266. Laouénan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Peytavin G, Mentré F, Guedj J
     Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir and Peg-IFN during triple therapy in treatment-experienced HCV infected cirrhotic patients (ANRS CO20-CUPIC).
     Agents Chemother., 2014, 58, 5332-5341
267. Laurain E, Ayav C, Erpelding ML, Kessler M, Briançon S, Brunaud L, Frimat L
     Targets for parathyroid hormone in secondary hyperparathyroidism: is a « one-size-fits-all » approach appropriate? A prospective incident cohort study
     BMC Nephrol., 2014, 15, 132
268. Leheup BF, Piot E, Goetz C, Quilliot D, Niemier JY, Wary B, Ducrocq X.
     Withdrawal of Artificial Nutrition: Influence of Prior Experience on the Perception of Caregivers.
     J. Hosp. Palliat. Care, 2014, [Epub ahead of print]
269. Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S; on behalf of the HALLMARK-DUAL Study Team
     All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
     Lancet. 2014, 384, 1597-1605
270. Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM
     Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
     Liver Int., 2014, 34, 707-719
271. Piard J, Mignot B, Arbez-Gindre F, Aubert D, Morel Y, Roze V, McElreavy K, Jonveaux P, Valduga M, Van Maldergem L.
     Severe sex differentiation disorder in a boy with a 3.8 Mb 10q25.3-q26.12 microdeletion encompassing EMX2.
     J. Med. Genet. A., 2014, 164A, 2618-2622
272. Poreaux C, Bronowicki JP, Debouverie M, Schmutz JL, Waton J, Barbaud A
     Clinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization
     Exp. Allergy, 2014, 44, 756-764
273. Raffaelli M, Brunaud L, De Crea C, Hoche G, Oragano L, Bresler L, Bellantone R, Lombardi CP
     Synchronous bilateral adrenalectomy for Cushing’s syndrome: laparoscopic versus posterior retroperitoneoscopic versus robotic approach
     World J. Surg., 2014, 38, 709-715
274. Rondon C, Campo P, Zambonino MA, Blanca-Lopez N, Torres MJ, Melendez L, Herrera R, Guéant-Rodriguez RM, Guéant JL, Canto G, Blanca M
     Follow-up in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis.
     Allergy Clin. Immunol., 2014, 133, 1026-1031
275. Thevenon J, Milh M, Feillet F, St-Onge J, Duffourd Y, Jugé C, Roubertie A, Héron D, Mignot C, Raffo E, Isidor B, Wahlen S, Sanlaville D, Villeneuve N, Darmency-Stamboul V, Toutain A, Lefebvre M, Chouchane M, Huet F, Lafon A, de Saint Martin A, Lesca G, El Chehadeh S, Thauvin-Robinet C, Masurel-Paulet A, Odent S, Villard L, Philippe C, Faivre L, Rivière JB
     Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathywith seizure onset in the first days of life.
     J. Hum. Genet., 2014, 95, 113-120
276. Vierling JM, Zeuzem S, Poordad F, Bronowicki JP, Manns MP, Bacon BR, Esteban R, Flamm SL, Kwo PY, Pedicone LD, Deng W, Dutko FJ, DiNubile MJ, Koury KJ, Helmond FA, Wahl J, Bruno S
     Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials.
     Hepatol., 2014, 61, 200-209
277. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R; VALENCE Investigators dont Bronowcki JP
     Sofosbuvir and ribavirin in HCV genotypes 2 and 3
     Engl. J. Med., 2014, 370, 1993-2001

278. About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L; ANRS CO20-CUPIC study group
     Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
     PLoS One, 2015, 10, e0145105
279. Adhoute X, Penaranda G, Bronowicki JP, Raoul JL
     Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort
     J Hepatol., 2015, 62, 492-493
280. Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Folgoc GL, Castellani P, Bronowicki JP, Bourlière M
     Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process
     Hepatol., 2015, 62, 855-862
281. Amet S, Bronowicki JP, Thabut D, Zoulim F, Bourliere M, Mathurin P, de Ledinghen V, Benhamou Y, Larrey DG, Janus N, Deray G, Launay-Vacher V, Pol S
     Prevalence of renal abnormalities in chronic HBV infection: The HARPE study.
     Liver Int., 2015,35,148-155
282. Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ
     ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
     PLoS One, 2015, 10, e0144004
283. Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F; CUPIC Study Group.
     Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study
     Res. Hepatol; Gastroenterol., 2015, 39, 443-450
284. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S.
     Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
     Lancet Infect. Dis., 2015, 15, 397-404
285. Brioude F, Netchine I, Praz F, Le Jule M, Calmel C, Lacombe D, Edery P, Catala M, Odent S, Isidor B, Lyonnet S, Sigaudy S, Leheup B, Audebert-Bellanger S, Burglen L, Giuliano F, Alessandri JL, Cormier-Daire V, Laffargue F, Blesson S, Coupier I, Lespinasse J, Blanchet P, Boute O, Baumann C, Polak M, Doray B, Verloes A, Viot G, Le Bouc Y, Rossignol S
     Mutations of the Imprinted CDKN1C Gene as a Cause of the Overgrowth Beckwith-Wiedemann Syndrome: Clinical Spectrum and Functional Characterization
     Mutat., 2015, 36, 894-902
286. Filipozzi P, Ayav C, Erpelding ML, Kessler M, Brunaud L, Frimat L
     Influence on quality of life from an early cinacalcet prescription for secondary hyperparathyroidism in dialysis
     Pharmacoepidemiol Drug Saf, 2015, 24, 187-96
287. Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D
     Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma
     Oncol., 2015, 115, 211-216
288. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B
     Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial
     Lancet, 2015, 385, 1075-1086
289. Nomine-Criqui C, Brunaud L, Germain A, Klein M, Cuny T, Ayav A, Bresler L
     Robotic lateral transabdominal adrenalectomy
     Oncol., 2015, 112, 305-9
290. Piot E, Leheup BF, Goetz C, Quilliot D, Niemier JY, Wary B, Ducrocq X.
     Caregivers Confronted With the Withdrawal of Artificial Nutrition at the End of Life: Prevalence of and Reasons for Experienced Difficulties.
     J. Hosp. Palliat. Care, 2015, 32, 732-737
291. Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH study group
     High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced null-responder HIV/HCV genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.
     Infect. Dis., 2015, 61, 817-825
292. Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Bräu N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Lédinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD; UNITY-1 Study Group.
     Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
     JAMA, 2015, 313, 1728-1735
293. Sultanik P, Mallet V, Lagaye S, Casrouge A, Dorival C, Barthe Y, Fontaine H, Hézode C, Mottez E, Bronowicki JP, Carrat F, Theodorou I, Abel L, Gayat E, Fontanet A, Pol S, Albert ML; ANRS CO20-CUPIC
     Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy
     Liver Int., 2015, 35, 1833-1844
294. Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S; and the ANRS CO12 CirVir Group.
     Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
     Hepatology, 2015, 62, 737-750
295. Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Müllhaupt B, Roberts S, Schuchmann M, Manns M, Bourlière M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Böcher W, Mensa FJ; SOUND-C2 Study Group
     Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis
     Agents Chemother., 2015, 59, 1282-1291
296. Adhoute X, Pénaranda G, Raoul JL, Blanc JF, Edeline J, Conroy G, Perrier H, Pol B, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Bronowicki JP, Bourlière M
     Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study
     J. Gastroenterol. Hepatol., 2016, 28, 433-440
297. Agopiantz M, Elhanbali O, Demore B, Cuny T, Demarquet L, Ndiaye C, Barbe F, Brunaud L, Weryha G, Klein M
     Thyroid side effects prophylaxis in front of nuclear power plant accidents
     Endocrinol. (Paris). 2016 , 77,1-6
298. Battini S, Imperiale A, Taïeb D, Elbayed K, Cicek AE, Sebag F, Brunaud L, Namer IJ
     High-resolution magic angle spinning 1H nuclear magnetic resonance spectroscopy metabolomics of hyperfunctioning parathyroid glands
     Surgery, 2016, 160, 384-394
299. Bekkar S, Gronnier C, Renaud F, Duhamel A, Pasquer A, Théreaux J, Gagnière J, Meunier B, Collet D, Mariette C; French Eso-Gastric Tumors (FREGAT) working group, Fédération de Recherche EN CHirurgie (FRENCH) and Association Française de Chirurgie (AFC).( dont Brunaud L)
     Multicentre study of neoadjuvant chemotherapy for stage I and II oesophageal cancer
     J. Surg., 2016, 103, 855-62
300. Brunaud L, Ngueyon Sime W, Filipozzi P, Nomine-Criqui C, Aronova A, Zarnegar R, Kessler M, Frimat L, Ayav C
     Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis
     Surgery, 2016, 159, 183-92
301. Finnerty BM, Brunaud L, Mirallie E, McIntyre C, Aronova A, Fahey TJ 3rd, Zarnegar R
     Cost disparity between health care systems-it’s not the surgeons: A cost analysis of thyroid cancer care between the United States and France
     Surgery, 2016, 159, 132-41
302. Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
     CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1
     J. Radiol., 2016, 85, 103-112
303. Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R.
     TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON
     Radiology,. 2016, Jan 8:150667. [Epub ahead of print]
304. Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL.
     Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study
     Liver Int., 2016, doi: 10.1111/liv.13096
305. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ
     Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
     Hepatology, 2016, 63, 1430-1441
306. Lodewijk L, Kluijfhout WP, Kist JW, Stegeman I, Plukker JT, Nieveen van Dijkum EJ, Bonjer HJ, Bouvy ND, Schepers A, de Wilt JH, Netea-Maier RT, van der Hage JA, Burger JW, Ho G, Lee WS, Shen WT, Aronova A, Zarnegar R, Benay C, Mitmaker EJ, Sywak MS, Aniss AM, Kruijff S, James B, Grogan RH, Brunaud L, Hoch G, Pandolfi C, Ruan DT, Jones MD, Guerrero MA, Valk GD, Borel Rinkes IH, Vriens MR
     Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1 cm
     Langenbecks Arch Surg, 2016, 401, 365-73
307. Markar SR, Gronnier C, Pasquer A, Duhamel A, Beal H, Théreaux J, Gagnière J, Lebreton G, Brigand C, Meunier B, Collet D, Mariette C; FREGAT working group – FRENCH – AFC; FREGAT working group – FRENCH – AFC (dont Brunaud L)
     Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study
     J. Cancer, 2016, 56, 59-68
308. Metallo M, Groza L, Brunaud L, Klein M, Weryha G, Feigerlova E
     Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I(131) during Adolescence and Young Adulthood
     Int J Endocrinol, 2016, 2016, 7586482
309. Nell S, Brunaud L, Ayav A, Bonsing BA, Groot Koerkamp B, Nieveen van Dijkum EJ, Kazemier G, de Kleine RH, Hagendoorn J, Molenaar IQ, Valk GD; DMSG, Borel Rinkes IH, Vriens MR
     Robot-assisted spleen preserving pancreatic surgery in MEN1 patients
     Surg. Oncol., 2016 Jun 6. doi: 10.1002/jso.24315
310. Steib A, Degirmenci SE, Junke E, Asehnoune K, Figier M, Pericard C, Rohr S, Letessier E, Brunaud L, Vix M, Zobairi F, Grunebaum L, Toti F
     Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study
     Obes. Relat. Dis., 2016, 12, 613-621
311. Velay A, Jeulin H, Eschlimann M, Malvé B, Goehringer F, Bensenane M, Frippiat JP, Abraham P, Ismail A, Murray JM, Combet C, Zoulim F, Bronowicki JP, Schvoerer E
     Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.
     Viral. Hepat, 2016, 23, 387-398
312. Zeuzem S, Hezode C, Bronowicki J-P, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourliere M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S and Team L-S. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
     Hepatol., 2016, 64, 292-300

TEAM 2 – Metabolic-Genomic interactions in personalized medicine and therapeutic innovation of chronic inflammatory bowel diseases

1. Angioi, K., P. Kaminsky and L. Peyrin-Biroulet
   Infliximab for Severe Peripheral Ulcerative Keratopathy Revealing Crohn’s Disease.
   Inflammatory Bowel Diseases. 2011, 17, 866-867
2. Belle A, Bronowicki JP, Peyrin-Biroulet L
   Reactivation of viral hepatitis in immunosuppressed patient : an ounce of prevention is worth a pound of cure.
   Gastroenterology, 2011, 140, 360-362
3. Billioud V, Laharie D, Filippi J, Roblin X, Oussalah A, Chevaux JB, Hebuterne X, Bigard MA, Peyrin-Biroulet L
   Adherence to adalimumab therapy in Crohn’s disease : a French multicenter experience.
   Bowel Dis., 2011, 17, 152-159
4. Billioud V, Peyrin-Biroulet L
   Beclomathasone dipropionate : a second chance for topical steroids as maintenance therapy in ileal Crohn’s disease.
   Liver Dis., 2011, 43, 423-424
5. Billioud V, Sandborn WJ, Peyrin-Biroulet L
   Loss of response and need for adalimumab dose intensification in Crohn’s disease : a systematic review.
   J. Gastroenterol., 2011, 106, 674-684

6. Bouguen, G. and L. Peyrin-Biroulet
   Surgery for adult Crohn’s disease: what is the actual risk?
   2011, 60, 1178-1181.
7. Bouguen C, Chevaux JB, Peyrin-Biroulet L
   Recent advances in cytokines : Therapeutic implications for inflammatory bowel diseases ;
   World J. Gastroenterol., 2011, 17, 547-556
8. Buisson, A. and L. Peyrin-Biroulet
   Haematopoietic stem cell autotransplantation for refractory Crohn’s disease: Ready for prime time?
   Digestive and Liver Disease. 2011, 43, 925-926
9. Chevaux, J. B. and L. Peyrin-Biroulet
   Is the dose of thioguanine the key to better safety profile?
   Digestive and Liver Disease. 2011, 43, 96-97
10. Chevaux, J. B., L. Peyrin-Biroulet and M. P. Sparrow
    Optimizing Thiopurine Therapy in Inflammatory Bowel Disease.
    Inflammatory Bowel Diseases. 2011, 17, 1428-1435
11. Del Tedesco E, Roblin X, Laharie D, Peyrin-Biroulet L
    Does anti-TNF therapy influence the performance of mycobacterium tuberculosis antigen-specific interferon-gamma assays ? A French multicenter experience.
    Bowel Dis., 2011, 8, 1824
12. Germain, A., M. Klein and L. Brunaud
    Surgical management of adrenal tumors.
    Journal of Visceral Surgery. 2011, 148, E250-E261
13. Normand S, Delanoye-Crespin A, Bressenot A, Huot L, Grandjean T, Peyrin-Biroulet L, Lemoine Y, Hot D, Chamaillard M.
    Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury.
    Natl. Acad. Sci. U S A., 2011, 108, 9601-9606
14. Peyrin-Biroulet L, Lémann M
    Review article : remission rates achievable by current therapies for inflammatory bowel disease.
    Pharmacol. Ther., 2011, 33, 870-879
15. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ
    Long-term complications, extraintestinal manifestations and mortality in adult Crohn’s disease in population-based cohorts.
    Bowel Dis., 2011, 17, 471-478
16. Peyrin-Biroulet L, Loftus EV Jr, Tremaione WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ
    Perianal Crohn’s disease findings other than fistulas in a population-based cohort.
    Bowel Dis., 2011, Epub ahead of print
17. Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP
    The use of azathioprine in Crohn’s disease during pregnancy and in the post-operative setting : a worldwide survey of experts.
    Pharmacol. Ther., 2011, 33, 707-713
18. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA
    Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease.
    Gut, 2011, 60, 930-936
19. Peyrin-Biroulet, L., K. Khosrotehrani, F. Carrat, A. M. Bouvier, J. B. Chevaux, T. Simon, F. Carbonnel, J. F. Colombel, J. L. Dupas, P. Godeberge, J. P. Hugot, M. Lemann, S. Nahon, J. M. Sabate, G. Tucat and L. Beaugerie
    Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease.
    2011, 141, 1621-U1150.
20. Peyrin-Biroulet, L., M. Ferrante, F. Magro, S. Campbell, D. Franchimont, H. Fidder, H. Strid, S. Ardizzone, G. Veereman-Wauters, J. B. Chevaux, M. Allez, S. Danese and A. Sturm
    Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. Journal of Crohns & Colitis. 2011, 5, 477-483
21. Pillot, C., J. B. Chevaux, N. Petitpain and L. Peyrin-Biroulet
    Acute Hepatic Cytolysis Following H1N1 Vaccination in a Patient with Crohn’s Disease on Infliximab.
    Inflammatory Bowel Diseases. 2011, 17: 679-679.
22. Roblin X, Oussalah A, Chevaux JB, Sparrow M; Peyrin-Biroulet L
    Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice : a worldwide survey of experts;
    Bowel Dis., 2011, 17, 2480-2487
23. Billioud V, Gibot S, Massin F, oussalah A, Chevaux JB, Williet N, Bronowicki JP, Bigard MA, Guéant JL, Peyrin-Biroulet L
    Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn’s disease;
    Liver Dis., 2012, 44, 466-470
24. Billioud V, Peyrin-Biroulet L
    Can elderly people be treated safely with anti-TNF agents ?
    Bowel Dis., 2012, 18, 594-595
25. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L
    Review aticle : the natural history of postoperative Crohn’s disease recurrence.
    Pharmacol. Ther., 2012, 35, 625-633
26. Buisson A, Chevaux JB, Bommelaer G, Peyrin-Biroulet L
    Diagnosis, prevention and treatment of postoperative Crohn’s disease recurrence.
    Dig; Liver Dis., 2012, 44, 453-463
27. Buisson A, Cuny JF, Barbaud A, Schmutz JL, Bigard MA, Guéant JL, Peyrin-Biroulet L.
    Methotrexate for psoriosiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
    Pharmacol. Ther., 2012, 35, 1175-1180
28. Buisson A, Peyrin-Biroulet L.
    Complementary and alternative medicine in inflammatory bowel disease.
    Pharmacol. Ther., 2012, 35, 619-620
29. Buisson, A. and L. Peyrin-Biroulet
    Letter: anti-TNFs and psoriasis – friends or foes? Authors’ reply.
    Alimentary Pharmacology & Therapeutics. 2012, 36, 498-498
30. Chevaux JB, Vavricka SR, Rogler G, Lakatos PL, Schoepfer A, Peyrin-Biroulet L
    Mucosal healing with anti-TNF antibodies.
    Digestion, 2012, 86, Suppl. 1, 16-22

31. Chevaux, J. B., G. Fiorino, M. Frederic and L. Peyrin-Biroulet
    Capsule Endoscopy in Crohn’s Disease.
    Current Drug Targets. 2012, 13, 1261-1267.
32. Danese S, Peyrin-Biroulet L
    Editorial : Imagining inflammatory bowel disease : looking beyond the mucosa.
    Drug. Targets, 2012, 13, 1223
33. Danese S, Peyrin-Biroulet L
    IBD : mucosal healing-EXTENDing our knowledge in Crohn’s disease.
    Rev. Gastroenterol. Hepatol., 2012, 9, 309-311
34. Fiorino, G., L. Peyrin-Biroulet and S. Danese
    Bowel Damage Assessment in Crohn’s Disease by Magnetic Resonance Imaging.
    Current Drug Targets. 2012, 13, 1300-1307.
35. Jess T, Rungoe C, Peyrin-Biroulet L
    Risk of colorectal cancer in patients with ulcerative colitis : a meta-analyssis of population-based cohort studies;
    Gastroenterolo. Hepatol., 2012, 10, 639-645
36. Jostins L, Ripke S, Weersma RK, et al. International IBD Genetics Consortium (IIBDGC) (dont  Peyrin-Biroulet L)
    Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
    Nature, 2012 Nov 1;491(7422):119-24
37. Peyrin-Biroulet L, Billioud V, D’Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ.
    Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process.
    J. Gastroenterol., 2012, 107, 1770-1776
38. Peyrin-Biroulet L, Chevaux JB, Bouvier AM, Carrat F, Beaugerie L
    Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased.
    J. Gastroenterol., 2012, 107, 1443-1444
39. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF , International programme to Develop New Indexes for Crohn’s disease (IPNIC) group
    Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.
    Gut, 2012, 61, 241-247
40. Peyrin-Biroulet L, Danese S.
    Stopping infliximab in Crohn’s disease: still an ongoing STORI.
    Bowel Dis., 2012, 18, 2201-2202
41. Peyrin-Biroulet L, Gonzalez F, Dubuquy L, Rousseaux C, Dubuquoy C, Decourcelle C, Saudemonmt A, tachon M, Béclin E, Odou MF, Neut C, Colombel JF, Desreumaux P.
    Mesenteric fat as source of C eractive protein and as a trget for bacterial translocation in Crohn’s disease.
    Gut, 2012, 61, 78-85
42. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr.
    Surgery in a population –based cohort of Crohn’s disease from Olmsted County, Minnesota (1970-2004)
    J; Gastroenterol., 2012, 107, 1693-1701
43. Peyrin-Biroulet L, Lepage C, Jooste V, Guéant JL, Faivre J, Bouvier AM
    Colorectal cancer in inflammatory bowel diseases : a population-based study (1976-2008)
    Bowel Dis., 2012, 18, 2247-2251
44. Peyrin-Biroulet L, Pillot C, Oussalah A, Billioud V, Aissa N, Balde N, Williet N, Germain A, Lozniewski A, Bresler L, Guéant JL, Bigard MA
    Urinary tract infections in hospitalized inflammatory bowel disease patients : a 10-year experience.
    Bowel Dis., 2012, 18, 697-702
45. Peyrin-Biroulet, L
    Hot Topic: Treatment of Inflammatory Bowel Diseases: Where Do We Go from here?
    Current Drug Delivery. 2012, 9, 325-325.
46. Peyrin-Biroulet, L
    Mucosal healing in inflammatory bowel diseases: why, when and how to achieve it?
    Acta Endoscopica. 2012, 42, 237-238.
47. Williet N, Pillot C, Oussalah A, Billioud V, Chevaux JB, Bresler L, Bigard MA, Gueant JL, Peyrin-Biroulet L ;
    Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics ;
    Bowel Dis., 2012, 18, 1641-1646
48. Zallot C, Peyrin-Biroulet L.
    Clinical risk factors for complicated disease: how reliable are they?
    Dis., 2012, 30 Suppl 3, 67-72
49. Allen PB, Peyrin-Biroulet L.
    Moving towards disease modification in inflammatory bowel disease therapy.
    Opin. Gastroenterol., 2013, 29, 397-404
50. Babouri A, Buisson A, Bigard MA, Peyrin-Biroulet L
    Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease.
    Crohns Colitis, 2013, 7, 129-133
51. Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; for the CESAME Study Group.
    Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer
    Gut, 2013, 63, 1416-143
52. Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L.
    Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
    Crohns Colitis, 2013, 7, 853-867
53. Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, Bigard MA, Peyrin-Biroulet L.
    Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab.
    Gastroenterol. Hepatol., 2013,11, 975-981.e1-4
54. Bressenot A, Chevaux JB, Williet N, Oussalah A, Grmain A, Gauchotte G, Wissler MP, Vignaud JM, Bresler L, Bigard MA, Plénat F, Guéant JL, Peyrin-Biroulet L
    Submucosal plexitis as a predictor of postoperative surgical recurrence in Crohn’s disease.
    Bowel Dis., 2013, 19, 1654-1661
55. Bressenot A, Geboes K, Vignaud JM, Guéant JL, Peyrin-Biroulet L
    Microscopic features for initial diagnosis and disease activity evaluatin in inflammatory bowel disease.
    Bowel Dis., 2013, 19, 1745-1752
56. Bressenot A, Pooya S, Bossenmeyer-Pourié C, Gauchotte G, Germain A, Chevaux JB, Coste F, Vignaud JM, Guéant JL, Peyrin-Biroulet L
    Methyl donor deficiency affects small-intestinal differenciation and barrier function in rats;
    J. Nutr., 2013, 109, 667-677
57. Buisson A, Chevaux JB, Hudziak H, Bresler L, Bigard MA, Peyrin-Biroulet L.
    Colonoscopic perforations in inflammatory bowel disease: a retrospective study in a French referral centre.
    Liver Dis., 2013, 45, 569-572
58. Buisson A, Seigne AL, Dʼhuart MC, Bigard MA, Peyrin-Biroulet L.
    The extra burden of infliximab infusions in inflammatory bowel disease.
    Bowel Dis., 2013, 19, 2464-2467
59. Chamaillard M, Chevaux JB, Peyrin-Biroulet L.
    Looking beyond histological healing in ulcerative colitis: towards the establishment of a molecular signature for quiescent but progressive disease.
    Gut, 2013 , 62, 959-960
60. Chevaux, J. B. and P. Bulois
    Management of intestinal strictures in inflammatory bowel disease.
    Acta Endoscopica. 2013, 43, 129-133.
61. Danese S, Peyrin-Biroulet L
    New mechanisms and targets for IBD therapy : translational gastroenterology comes of age.
    Drug. Targets, 2013, 14, 1377-1378

62. Ford AC, Peyrin-Biroulet L.
    Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.
    J. Gastroenterol., 2013, 108, 1268-1276
63. Gower-Rousseau C, Savoye G, Colombel JF, Peyrin-Biroulet L
    Are we improving disease outcomes in IBD ? A view from the epidemiology side.
    Gut, 2013, [Epub ahead of print]
64. Laharie D, Filippi J, Roblin X, Nancey S, Chevaux JB, Hébuterne X, Flourié B, Capdepont M, Peyrin-Biroulet L.
    Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience.
    Pharmacol. Ther., 2013, 37, 998-1004
65. Laharie D, Filippi J, Roblin X, Nancey S, Peyrin-Biroulet L
    Letter: mucosal healing in ulcerative colitis–higher relevance than in Crohn’s disease? Authors’ reply.
    Aliment Pharmacol Ther., 2013, 38, 208
66. Leon, A., F. Barbe, C. Rabaud and I. Aimone-Gastin
    An unusual interference in CK MB assay caused by a macro enzyme creatine phosphokinase (CK) type 2 in HIV-infected patients.
    Clinical Chemistry and Laboratory Medicine. 2013, 51: E27-E29.
67. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L.
    Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review.
    Bowel Dis., 2013, 19, 1528-1533
68. Lopez A, Peyrin-Biroulet L
    5-aminosalicylic acid and chemoprevention : does it work ?
    Dis., 2013, 31, 248-253
69. Petitpain N, Bornert-Keller N, Peyrin-Biroulet L.
    Acute coronary syndrome in a Crohn’s disease patient treated with adalimumab.
    Crohns Colitis, 2013, 7, e396

70. Peyrin-Biroulet L
    Tumor necrosis factor inhibitors for inflammatory bowel disease.
    Engl. J. Med., 2013, 369, 2561
71. Peyrin-Biroulet L, Bonnaud G, Bourreille A, Chevaux JB, Faure P, Filippi J, Laharie D, Vuitton L, Bulois P, Gonzalez F, Trang C, Koch S, Bernardini D, Cellier C; IBD Committee of the French Society of Digestive Endoscopy.
    Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED).
72. Peyrin-Biroulet L, Danese S
    Leukoaphreresis in Crohn’s disease : the final curtain ?
    Gut, 2013, 62, 487-488

73. Peyrin-Biroulet L, Danese S.
    Tofacitinib: janus bifrons in ulcerative colitis treatment.
    Gastroenterology, 2013, 144, 1136-1138
74. Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S.
    First-line therapy in adult Crohn’s disease: who should receive anti-TNF agents?
    Rev. Gastroenterol. Hepatol., 2013, 10, 345-351
75. Peyrin-Biroulet L.
    Advances in the treatment of ulcerative colitis.
    Hepatol. (N Y), 2013, 9,827-829
76. Peyrin-Biroulet L.
    Disease-modifying anti-inflammatory bowel disease drugs (DMAIDs): the missing term in the literature.
    J. Gastroenterol., 2013, 108, 859-860
77. Peyrin-Biroulet, L
    Endoscopy and IBD: why do we update the SFED recommendations?
    Acta Endoscopica. 2013, 43: 109-109.
78. Rinaudo-Gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-Biroulet L
    Review article : biosimilars are the next generation of drugs for liver and gastrointestinal diseases;
    Pharmacol. Ther., 2013, 38, 914-924
79. Vuitton L, Koch S, Peyrin-Biroulet L
    Preventing postoperative recurrence in Crohn’s disease : what does the future hold ?
    Drugs, 2013, 73, 1749-1759
80. Vuitton L, Koch S, Peyrin-Biroulet L.
    Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
    Drug Targets, 2013, 14, 1385-1391
81. Williet N, Peyrin-Biroulet L.
    Letter: fatigue, a growing concern in inflammatory bowel diseases.
    Pharmacol. Ther., 2013, 38, 442

82. Zallot C, Billioud V, Frimat L, Faure P, Peyrin-Biroulet L; CREGG (Club de reflexion des cabinets et groupes d’Hépatogastroentérologie)
    5-aminosalicylates and renal function monitoring in inflammatory bowel disease : a nationwide survey.
    Crohns Colitis, 2013, 7, 551-555
83. Zallot C, Peyrin-Biroulet L.
    Deep remission in inflammatory bowel disease: looking beyond symptoms.
    Gastroenterol. Rep., 2013, 15, 315
84. Zallot C, Quilliot D, Chevaux JB, Peyrin-Biroulet C, Guéant-Rodriguez RM, Freling E, Collet-Fenetrier B, Williet N, Ziegler O, Bigard Ma, Guéant JL, Peyrin-Biroulet L
    Dietary beliefs and behavior among inflammatory bowel disease patients ;
    Bowel Dis., 2013, 19, 66-72
85. Antunes O, Filippi J, Hébuterne X, Peyrin-Biroulet L.
    Treatment algorithms in Crohn’s – up, down or something else?
    Pract. Res. Clin. Gastroenterol., 2014, 28, 473-483
86. Asthana AK, Sparrow MP, Peyrin-Biroulet L.
    Optimizing conventional medical therapies in inflammatory bowel disease in 2014
    Curr; Drug Targets, 2014, 15, 1002-1010
87. Babouri A, Roblin X, Filippi J, Hébuterne X, Bigard MA, Peyrin-Biroulet L.
    Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: a prospective multicenter cohort study.
    Crohns Colitis, 2014, 8, 161-165
88. Bressenot A, Cahn V, Danese S, Peyrin-Biroulet L.
    Microscopic features of colorectal neoplasia in inflammatory bowel diseases.
    World J. Gastroenterol., 2014, 20, 3164-3172
89. Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L
    Comparing histological activity indexes in UC
    Gut, 2015, 64, 1412-1418
90. Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L.
    Catching the therapeutic window of opportunity in early Crohn’s disease
    Drug Targets, 2014, 15, 1056-1063
91. Danese S, Peyrin-Biroulet L
    Medical challanges in inflammatory bowel disease: quo vadis in disease complexity?

92. Danese S, Peyrin-Biroulet L
    IBD in 2013 : Enriching the therapeutic armamentarium for IBD.
    Rev. Gastroenterol. Hepatol., 2014, 11, 84-86
93. Danese S, Siegel CA, Peyrin-Biroulet L.
    Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
    Pharmacol. Ther., 2014, 39, 1095-1103
94. Duchesne C, Faure P, Kohler F, Pingannaud MP, Bonnaud G, Devulder F, Abramowitz L, Boustière C, Peyrin-Biroulet L; CREGG (Club de Reflexion des cabinets et Groupes d’Hépato-Gastroentérologie).
    Management of inflammatory bowel disease in France: A nationwide survey among private gastroenterologists.
    Liver Dis., 2014, 46, 675-681
95. Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L.
    Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.
    Gut, 2014, 63, 1843-1853
96. Dulai PS, Siegel CA, Peyrin-Biroulet L
    Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD
    Clin. North Am., 2014, 43, 441-456. Review
97. Dulai PS, Siegel CA, Peyrin-Biroulet L.
    Anti-Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD.
    Clin. North. Am., 2014, 43, 441-456
98. Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L
    Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease
    Pharmacol. Ther., 2014, 40, 3-15
99. Hindryckx P, Baert F, Hart A, Armuzzi A, Panès J, Peyrin-Biroulet L; The Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO).
    Clinical trials in luminal Crohn’s disease: A historical perspective.
    Crohns Colitis., 2014, pii: S1873-9946(14)00152-4
100. Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L.
     Thiopurines and Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease: A Meta-analysis.
     Gastroenterol. Hepatol., 2014, 12, 1793-1800
101. Lakatos PL, Peyrin-Biroulet L.
     Azathioprine in early Crohn’s disease: time to revisit patient selection and end points for clinical trials and/or azathioprine efficacy?
     Gastroenterology, 2014, 146, 867-868
102. Lopez A, Beaugerie L, Peyrin-Biroulet L
     Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
     Expert Rev; Clin; Immunol., 2014, 10, 1563-1565
103. Manginot C, Baumann C, Peyrin-Biroulet L.
     An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis
     Gut, 2014, pii: gutjnl-2014-308839 [Epub ahead of print]
104. Peyrin-Biroulet L
     Deep remission in Crohn’s disease ; is it the end of the placebo effect ?
     Gastroenterol. Hepatol.,2014, 12, 347
105. Peyrin-Biroulet L, Bressenot A, Kampman W.
     Histologic remission: the ultimate therapeutic goal in ulcerative colitis?
     Gastroenterol. Hepatol., 2014, 12, 929-34.e2
106. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mntzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornille FJ, Sandborn WJ
     Clinical disease activity, C-reactive protein normlisation and mucosal healing in Crohn’s disease in the SONIC trail.
     Gut, 2014, 63, 88-95
107. Roblin X, Danese S, Peyrin-Biroulet l
     Does anti-TNF therapy cost so many COINs ?
     Gastroenterology, 2014, 146, 309-311

108. Williet N, Sandborn WJ, Peyrin-Biroulet L.
     Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease.
     Gastroenterol. Hepatol., 2014, 12, 1246-1256.e6
109. Amiot A, Peyrin-Biroulet L
     Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
     Adv. Gastroenterol., 2015, 8, 66-82
110. Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Guéant JL, Bronowicki JP, Peyrin-Biroulet L
     Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases
     Eur J Gastroenterol Hepatol. 2015, 2, 877-881
111. Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L
     Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn’s disease
     Bowel Dis., 2015, 21, 1047-1053
112. Bressenot A, Peyrin-Biroulet L
     Histologic features predicting postoperative Crohn’s disease recurrence
     Bowel Dis., 2015, 21, 468-475
113. Carla-Moreau A, Paul S, Roblin X, Genin C, Peyrin-Biroulet L
     Prevention and treatment of postoperative Crohn’s disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials.
     Liver Dis. 2015, 47, 191-196
114. Danese S, Fiorino G, Peyrin-Biroulet L
     Targeting SMAD7 in Crohn’s Disease by Mongersen: Therapeutic Revolution Under Way?
     Gastroenterology, 2015, 149, 1121-1123
115. Danese S, Vuitton L, Peyrin-Biroulet
     Biologic agents for IBD: practical insights
     Rev. Gastroenterol. Hepatol., 2015, 12, 537-545
116. de Chambrun GP, Dauchet L, Gower-Rousseau C, Cortot A, Colombel JF, Peyrin-Biroulet L
     Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies.
     Clinical Gastroenterology and Hepatology. 2015, 13, 1405-.
117. d’Huart MC, Chevaux JB, Bressenot AM, Froment N, Vuitton L, Degano SV, Latarche C, Bigard MA, Courrier A, Hudziak H, Koch S, Kull E, Peyrin-Biroulet L
     Prevalence of esophageal squamous papilloma (ESP) and associated cancer in northeastern France
     Endosc Int Open, 2015, 3, E101-106
118. Filipe V, Allen PB, Peyrin-Biroulet L
     Self-medication with steroids in inflammatory bowel disease
     Liver Dis., 2015 Oct 17. pii: S1590-8658(15)00656-8. doi: 10.1016/j.dld.2015.10.010. [Epub ahead of print]
119. Fréling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, Peyrin-Biroulet L
     Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience
     Am J Gastroenterol, 2015, 110, 1186-1196
120. Fumery M, de Chambrun GP, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas JP, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhnik Y, Peyrin-Biroulet L.
     Detection of Dysplasia or Cancer in 3.5% of Patients with Inflammatory Bowel Disease and Colonic Strictures
     Gastroenterol. Hepatol., 2015, 13, 1770-1775
121. Germain A, Guéant RM, Chamaillard M, Bresler L, Guéant JL, Peyrin-Biroulet L
     CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn’s disease
     Dig Liver Dis, 2015, 47, 938-942
122. Gizard E, Kalouche I, Merlin P, Peyrin-Biroulet L
     Ileal ulcers not responding to infliximab therapy: think about intestinal ganglioneuromatosis
     Liver Dis. 2015, 47, 257-258
123. Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-Biroulet L; Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO).
     Clinical Trials in Ulcerative Colitis: A Historical Perspective
     Crohns Colitis., 2015, pii: jjv074. [Epub ahead of print] Review
124. Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin-Biroulet L
     Systematic review: the financial burden of surgical complications in patients with ulcerative colitis
     Pharmacol. Ther., 2015, 41, 1066-1078
125. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L
     Iron deficiency anaemia
     Lancet, 2015, Aug 24. pii: S0140-6736(15)60865-0
126. Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L
     Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials
     Liver Dis., 2015, 47, 356-364
127. Marchal Bressenot A, Riddell RH, Boulagnon-Rombi C, Reinisch W, Danese S, Schreiber S, Peyrin-Biroulet L
     Review article: the histological assessment of disease activity in ulcerative colitis
     Pharmacol. Ther., 2015, 42, 957-967
128. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, Diebold MD, Danese S, Reinisch W, Schreiber S, Travis S, Peyrin-Biroulet L
     Development and validation of the Nancy histological index for UC
     Gut, 2015, Oct 13. pii: gutjnl-2015-310187. doi: 10.1136/gutjnl-2015-310187.

129. Paul S, Roblin X, Peyrin-Biroulet L
     Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease
     Pharmacol. Ther., 2015, 42, 939-940
130. Peyrin-Biroulet L
     Defining Severity in Inflammatory Bowel Disease
     Hepatol. (N Y), 2015, 11, 474-476
131. Peyrin-Biroulet L, Laurent V
     Is Diffusion-weighted Magnetic Resonance Imaging for Assessing Crohn’s Disease Ready for Prime Time? Experience with the Nancy Score
     Bowel Dis., 2015, 21, E25
132. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B.
     Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
     Gastroenterol. Hepatol., 2015 Jun 11. pii: S1542-3565(15)00787-9. doi: 10.1016/j.cgh.2015.06.001. [Epub ahead of print]
133. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O’Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF
     Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
     J. Gastroenterol., 2015, 110, 1324-1338
134. Peyrin-Biroulet L, Williet N, Cacoub P
     Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review
     J. Clin. Nutr., 2015, 102, 1585-1594
135. Peyrin-Biroulet L.
     Clinical remission as defined by the Mayo Score: do we deceive ourselves?
     Bowel Dis., 2015, 21, E2-3
136. Pineton de Chambrun G, Dauchet L, Gower-Rousseau C, Cortot A, Colombel JF, Peyrin-Biroulet L
     Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies
     Gastroenterol. Hepatol., 2015, pii: S1542-3565(15)00638-2 [Epub ahead of print]
137. Reinhard A, Sandborn WJ, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L
     Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions
     Rev? Clin. Immunol., 2015, 11, 637-657
138. Saadoune N, Peyrin-Biroulet L, Baumann C, Bigard MA, Wirth N, Martinet Y, Peyrin-Biroulet C
     Beliefs and behaviour about smoking among inflammatory bowel disease patients
     J. Gastroenterol. Hepatol., 2015, 2, 797-803
139. Schreiber S, Panés J, Kwon B, Hong S, Peyrin-Biroulet L
     Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13
     Expert Rev. Gastroenterol. Hepatol., 2015;9 Suppl 1:5-15
140. Tréchot F, Angioi K, Latarche C, Conroy G, Beaujeux P, Andrianjafy C, Portier M, Batta B, Conart JB, Cloché V, Peyrin-Biroulet L
     Keratoconus in Inflammatory Bowel Disease Patients: A Cross-sectional Study
     Crohns Colitis, 2015, 9, 1108-1112
141. Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D’Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L
     IOIBD technical review on endoscopic indices for Crohn’s disease clinical trials
     Gut, 2015, Sep 9. pii: gutjnl-2015-309903. doi: 10.1136/gutjnl-2015-309903. [Epub ahead of print]
142. Vuitton L, Peyrin-Biroulet L
     The POCER Trial: Bet on Active Care
     Gastroenterology, 2015, 148, 1474-1475
143. Allen PB, Peyrin-Biroulet L.
     Immunomodulators for the treatment of Crohn’s disease in adults: optimal use and prospects for future drug treatments
     Expert Rev. Clin. Immunol., 2016, 12, 1-9
144. Bressenot AM, Peyrin-Biroulet L
     Letter: histological assessment of disease activity in ulcerative colitis–the problem of score evaluation and validation; authors’ reply
     Pharmacol. Ther., 2016, 43, 439
145. Conroy G, Clerc-Urmès I, Allen PB, Baumann C, Peyrin-Biroulet L
     What Proportion of Patients With Inflammatory Bowel Disease Want to Stop Infliximab Therapy?
     Bowel Dis., 2016 Jun 6. [Epub ahead of print]
146. Danese S, Hart A, Dignass A, Louis E, D’Haens G, Dotan I, Rogler G, D’Agay L, Iannacone C, Peyrin-Biroulet L.
     Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
     BMJ Open Gastroenterol., 2016, 3, e000092
147. Germain A, Guéant RM, Chamaillard M, Allen PB, Bresler L, Guéant JL, Peyrin-Biroulet L
     NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn’s disease: A genetic association study
     Surgery, 2016, 160, 74-80
148. Guinet-Charpentier C, Lepage P, Morali A, Chamaillard M, Peyrin-Biroulet L
     Effects of enteral polymeric diet on gut microbiota in children with Crohn’s disease
     Gut, 2016, Jan 27. pii: gutjnl-2015-311058. doi: 10.1136/gutjnl-2015-311058
149. Lopez A, Collet-Fenetrier B, Belle A, Peyrin-Biroulet L.
     Patient’s knowledge and fear about colorectal cancer risk in inflammatory bowel disease
     Dig. Dis. 2016, Apr 29. doi: 10.1111/1751-2980.12356
150. Papamichael K, Mantzaris GJ, Peyrin-Biroulet L
     A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease
     Expert Opin. Drug Saf., 2016, 15, 493-501
151. Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X; gastroenterologist nominal group
     French national consensus clinical guidelines for the management of ulcerative colitis
     Liver Dis., 2016, pii: S1590-8658(16)30385-1. doi: 10.1016/j.dld.2016.03.029
152. Peyrin-Biroulet L, Danese S
     Early Combined Immunosuppression in Crohn’s Disease: Acting Rather Than REACTing
     Gastroenterology, 2016, 150, 1040-1041
153. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr
     Cumulative Length of Bowel Resection in a Population-based Cohort of Patients With Crohn’s Disease
     Gastroenterol. Hepatol., 2016 May 4. pii: S1542-3565(16)30144-6. doi: 10.1016/j.cgh.2016.04.031
154. Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X.
     Anti-TNF Monotherapy for Crohn’s Disease: a 13-year Multicentre Experience
     Crohns Colitis, 2016, 10, 516-24
155. Peyrin-Biroulet L, Van Assche G, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S
     Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study
     Liver Dis., 2016, 48, 601-607
156. Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L
     Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease
     Expert Rev. Gastroenterol. Hepatol., 2016, 18, 1-13
157. Roblin X, Williet N, Peyrin-Biroulet L
     Thiopurine Metabolism in the Era of Combotherapy
     Bowel Dis., 2016, 22, 1496-1501
158. Salleron J, Danese S, D’Agay L, Peyrin-Biroulet L
     Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge
     Crohns Colitis, 2016 Mar 3. pii: jjw068
159. Salleron J, Peyrin-Biroulet L
     Reply to: Dr Macaluso’s Letter
     Crohns Colitis, 2016, Apr 27. pii: jjw097
160. Sandborn, W., J. F. Colombel, G. D’Haens, S. Ghosh, R. Panaccione, J. Panes, S. Travis and L. Peyrin-Biroulet
     The Crohn’s Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice.
     Clinical Gastroenterology and Hepatology. 2016, 14, E121-E122
161. Taleban S, Elquza E, Gower-Rousseau C, Peyrin-Biroulet L
     Cancer and inflammatory bowel disease in the elderly
     Liver Dis., 2016, pii: S1590-8658(16)30423-6

162. Filippi J, Allen PB, Hébuterne X, Peyrin-Biroulet L
     Does anti-TNF therapy erduce the requirement for surgery in ulcerative colitis ? a systematic review;
     Drug Targets, 2011, 12, 1440-1447
163. Fiorino G, Bonifacio C, Peyrin-Biroulet L, Minuti F, Repici A, Spinelli A, Fries W, Balzarini L, Montorsi M, Malesci A, Danese S.
     Prospective comparison of computed tomography enterography and manetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn’s disease;
     Bowel Dis., 2011, 17, 1073-1080
164. Fiorino G, Peyrin-Biroulet L, Repici A, Malesci A, Danese S
     Adalimumab in ulcerative colitis : hypes and hopes.
     Expert Opin. Biol. Ther., 2011, 11, 109-116
165. Fiorino G, Szabo H, Walter F, Malesci A, Peyrin-Biroulet L, Danese S.
     Adalimumab in Crohn’s disease : tips and tricks after 5 years of clinical experience;
     Med. Chem., 2011, 18 1230-1238
166. Leblanc S, Allez M, Seksik P, Flourié B, Peeters H, Dupas JL, Bouguen G, Peyrin-Biroulet L, Duclos B, Bourreille A, Dewit O, Bouhnik Y, Michetti P, Chaussade S, Saussure P, Mary JY, Colombel JF, Lémann M
     J. Gastroenterol., 2011, 106, 771-777
167. Rahier JF, Papay P ; Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, Garcia-Sanchez V, et al.
     H1N1 vaccines in a large observational cohort of patients with inflammatory bowel dsease treated with immunomodulators and biological therapy.
     Gut, 2011, 60, 456-462
168. Roblin X, pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phlip JM, Chambonnière ML, Garraud O, Peyrin-Biroulet L, Pozzetto B.
     Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis.
     J. Gastroenterol., 2011, 106, 2001-2008

169. Achleitner U, Coenen M, Colombel JF, Peyrin-Biroulet L, Sahakyan N, Cieza A
     Identification of areas of functioning and disability addressed in inflammatory bowel disease-specific patient reported outcome measures;
     Crohns Colitis, 2012, 6, 507-517
170. Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R.
     Deep remission: a new concept?
     Dis., 2012, 30, Suppl 3, 107-11
171. Fiorino G, Peyrin-Biroulet L, Naccarato P, Szabo H, Socale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S.
     Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease : a prospective study.
     Bowel Dis., 2012, 18, 1042-1047
172. Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S
     Treatment of extraintestinal manifestations in inflammatory bowel disease
     Digestion, 2012, 86, Suppl. 1, 28-35
173. Panaccionr R, Hibi T, Peyrin-Biroulet L, Schreiber S
     Implementing changes in clinical practice to improve the management of Crohn’s disease;
     Crohns Colitis, 2012, 6, Suppl 2, S235-S242
174. Schoepfer AM, Safroneeva E, Vavricka SR, Peyrin-Biroulet L, Mottet C
     Treatment of fibrostentic and fistulizing Crohn’s disease.
     Digestion, 2012, 86, Suppl. 1, 23-27
175. Torres J, Billioud V, Peyrin-Biroulet L, Colombel JF
     Ulcerative colitis as a sole mucosal disease : another misunderstanding ?
     Gut, 2012, 61, 633
176. Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF
     Ulcerative colitis as a progressive disease : the forgotten evidence;
     Bowel dis., 2012, 18, 1356-1363

177. Allen PB, Kamm MA, Peyrin-Biroulet L, Studd C, McDowell C, Allen BC, Connell WR, De Cruz PP, Bell SJ, Elliot RP, Brown S, Desmond PV, Lemann M, Colombel JF.
     Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease.
     Pharmacol. Ther., 2013, 37, 438-444
178. Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Fléjou JF, Carrat F; CESAME Study Group
     Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease..
     Gastroenterology, 2013, 145, 166-175.e8
179. Boualit M, Salleron J, Turck D, Fumery M, Savoye G, Dupas JL, Lerbours E, Duhamel , merle V, Cortot A, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C; EPIMAD Group
     Long-term outvomr after first intestinal resection in pediatric-onset Crohn’s disease : a population-based study.
     Bowel Dis., 2013, 19, 7-14
180. Bouguen G, Levesque BG, feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Snadborn WJ.
     Treat to target : a proposed new paradigm for the management of Crohn’s disease;
     Gastroenterol. Hepatol., 2013, pii, S1542-3565 (13) 1301-1303]
181. Chapuis J, Hansmannel F, Gistelinck M, Mounier A, Van Cauwenberghe C, Kolen KV, Geller F, Sottejeau Y, Harold D, Dourlen P, Grenier-Boley B, Kamatani Y, Delepine B, Demiautte F, Zelenika D, Zommer N, Hamdane M, Bellenguez C, Dartigues JF, Hauw JJ, Letronne F, Ayral AM, Sleegers K, Schellens A, Broeck LV, Engelborghs S, De Deyn PP, Vandenberghe R, O’Donovan M, Owen M, Epelbaum J, Mercken M, Karran E, Bantscheff M, Drewes G, Joberty G, Campion D, Octave JN, Berr C, Lathrop M, Callaerts P, Mann D, Williams J, Buée L, Dewachter I, Van Broeckhoven C, Amouyel P, Moechars D, Dermaut B, Lambert JC; GERAD consortium
     Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
     Mol Psychiatry, 2013, 18, 1225-1234
182. Chauvin C, Peyrin-Biroulet L, Chamaillard M, Poulin LF
     Phagocytes migration in response to an emergency call from he microbiota.
     Gastroenterology, 2013, 145, 1150-1151
183. Cloché V, Buisson A, Tréchot F, Batta B, Locatelli A, Favel C, Premy S, Collet-Fenetrier B, Fréling E, Lopez A, Massoure MP, Humbert AL, Hansmannel F, Guéant JL, Bigard MA, Peyrin-Biroulet L, Angioi K
     Ocular symptoms are not predictive of ophtalmologic inflammation in inflammatory bowel disease.
     Dig; Liver Dis., 2013,45, 195-199
184. Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Peyrin-Biroulet L, Caprioli F, Passini N, Panina-Bordignon P, Repici A, Malesci A, Rutella S, Rescigno M, Danese S
     Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response.
     Gastroenterology, 2013, 144, 346-346
185. Couturier-Maillard A, Secher T, Rehman A, Normand S, De Arcangelis A, Haesler R, Huot L, Grandjean T, Bressenot A, Delanoye-Crespin A, Gaillot O, Schreiber S, Lemoine Y, Ryffel B, Hot D, Nùñez G, Chen G, Rosenstiel P, Chamaillard M.
     NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer.
     Clin. Invest., 2013, 123, 700-711
186. Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W.
     Review article: the role of anti-TNF in the management of ulcerative colitis — past, present and future.
     Pharmacol. Ther., 2013, 37, 855-866
187. Fiorino G, Bonifacio C, Padrenostro M, Sposta FM, Spinelli A, Malesci A, Balzarini L, Peyrin-Biroulet L, Danese S.
     Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn’s disease.
     Dis. Sci., 2013, 58; 3246-3255
188. François A, Salvadori A, Bressenot A, Bezdetnaya L, Guillemin F, D’Hallewin MA.
     How to avoid local side effects of bladder photodynamic therapy: impact of the fluence rate.
     Urol., 2013, 190, 731-736
189. Gower-Rousseau C, VasseurF, Fumery M, Savoy G, salleron J, Dauchet L, Turck D, Cortot A, Peyrin-Biroulet L, Colombel J
     Epidemilogy of inflammatory bowel diseases : new insights from a French population-based registry (EPIMAD)
     Liver Dis., 2013, 45, 89-94
190. Lafitte M, Ayav A, Bressenot A, Claudon M, Regent D, Laurent V
     Radiologic-pathologic correlation in liver angiomyolipoma in a 68-year-old woman.
     Interv. Imaging., 2013, 94, 1161-1164
191. Nuij VJ, Zelinkova Z, Rijk MC, Beukers R, Ouwendijk RJ, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ; Dutch Delta IBD Group.
     Phenotype of inflammatory bowel disease at diagnosis in the Netherlands: a population-based inception cohort study (the Delta Cohort).
     Bowel Dis., 2013, 19, 2215-2222
192. Panaccione R, Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ.
     Evolving definitions of remission in Crohn’s disease.
     Bowel Dis., 2013, 19, 1645-1653
193. Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, Danese S, Halligan S, Marincek B, Matos C, Peyrin-Biroulet L, Rimola J, Rogler G, van Assche G, Ardizzone S, Ba-Ssalamah A, Bali MA, Bellini D, Biancone L, Castiglione F, Ehehalt R, Grassi R, Kucharzik T, Maccioni F, Maconi G, Magro F, Martín-Comín J, Morana G, Pendsé D, Sebastian S, Signore A, Tolan D, Tielbeek JA, Weishaupt D, Wiarda B, Laghi A.
     Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.
     Crohns Colitis, 2013, 7, 556-585
194. Paul S, Del Tedesco E, Marotte H, Rinaudo-Gaujus M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X
     Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease : a prospective study.
     Bowel Dis., 2013, 19, 2568-2576
195. Peneau A, Savoye G; Turck D, Dauchet L, Fumery M,, Salleron J, Lerbours E, Ligier K, Vasseur F, Dupas JL, Mouterde O, Spyckerlle C, Djeddi D, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C
     Mortality and cancer inpediatric-onset inflammatory bowel disease : a population-based study.
     J; Gastroenterol., 2013, 108, 1647-1653
196. Reinisch W, Chowers Y, Danese S, Dignass A, Gomollon F, Nielsen OH, Lakatos PL, Lees CW, Lindgren S, Luka M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H.
     The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method.
     Pharmacol. Ther; 2013, 38, 1109-1118
197. Rogler G, Aldeguer X, Kruis W, Lasson A, Mittmann U, Nally K, Peyrin-Biroulet L, Schoepfer A, Vatn M, Vavricka S, Logan R.
     Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.
     Crohns Colitis, 2013, 7, 670-677
198. Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR, IBD Cohort study Group
     Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate.
     J. Gastroenterol., 2013, 108, 1744-1753
199. Sedhom MA, Pichery M, Murdoch JR, Foligné B, Ortega N, Normand S, Mertz K, Sanmugalingam D, Brault L, Grandjean T, Lefrancais E, Fallon PG, Quesniaux V, Peyrin-Biroulet L, Cathomas G, Junt T, Chamaillard M, Girard JP, Ryffel B.
     Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice.
     Gut, 2013, 62, 1714-1723
200. Serradori T, Germain A, Scherrer ML, Ayav C, Perez M, Romain B, Palot JP, Rohr S, Peyrin-Biroulet L, Bresler L.
     The effect of immune therapy on surgical site infection following Crohn’s Disease resection.
     J. Surg., 2013, 100, 1089-1093
201. Tavernier N, Fumery M, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C.
     Systematic review : fertility in non-surgically treated inflammatory bowel disease.
     Pharmacol. Ther., 2013, 38, 847-853

202. Bodini G, Savarino V, Peyrin-Biroulet L, de Cassan C, Dulbecco P, Baldissarro I, Fazio V, Giambruno E, Savarino E
     Low serum trough levels are associated with post-surgical recurrence in Crohn’s disease patients undergoing prophylaxis with adalimumab
     Dig Liver Dis., 2014, 46, 1043-1046
203. Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, Vasseur F, Dupas JL, Cortot A, Dauchet L, Peyrin-Biroulet L, Lerebours E, Colombel JF, Gower-Rousseau C.
     Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.
     2014 Mar;63(3):423-32
204. D’Alessio S, Correale C, Tacconi C, Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli A, Peyrin-Biroulet L, Fiocchi C, Danese S.
     VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease.
     Clin. Invest., 2014, 124, 3863-3878
205. Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S.
     Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.
     Intern. Med., 2014, 160, 704-711
206. Delvincourt M, Lopez A, Pillet S, Bourrier A, Seksik P, Cosnes J, Carrat F, Gozlan J, Beaugerie L, Roblin X, Peyrin-Biroulet L, Sokol H.
     The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease.
     Pharmacol. Ther., 2014, 39, 712-720
207. Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, peyrin-Biroulet L, Colombel JF.
     Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases : a meta-analysis of observational studies.
     Crohns Colitis, 2014, 8, 469-479
208. Gomollón F, Chowers Y, Danese S, Dignass A, Haagen Nielsen O, Lakatos PL, Lees CW, Lindgren S, Lukas M, Mantzaris GJ, Michetti P, Moum B, Peyrin-Biroulet L, Toruner M, van der Woude J, Weiss G, Stoevelaar H, Reinisch W.
     Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicines.
     Pharmacol Ther., 2014, 39, 743-744
209. Javot L, Pere P, Got I, Petitpain N, Peyrin-Biroulet L, Gillet P.
     Hypertrigyceridemia during infliximab therapy.
     Joint Bone Spine, 2014, 81, 94-96
210. Leclerc-Jacob S, Lux G, Rat AC, Laurent V, Blum A, Chary-Valckenaere I, Peyrin-Biroulet L, Loeuille D.
     The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients.
     Pharmacol. Ther., 2014, 39, 957-962
211. Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadié M, Beaugerie L, Peyrin-Biroulet L; CESAME Study Group.
     Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
     Gastroenterol. Hepatol., 2014, 12, 1324-1329
212. Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins PD, Joyce JC, Katsanos KH, Lopez A, de Xaxars TM, Toader E, Beaugerie L.
     Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
     Crohns Colitis, 2014, 8, 31-44
213. Moreau AC, Pul S, Del Tedesco E, Rinaudo-Gaujus M, Boukhadra N, Genin C, Peyrin-Biroulet L, Roblin X
     Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease : a meta-analysis;
     Bowel Dis., 2014, 20, 464-471
214. Nahon S, Lahmek P, Lesgourgues B, Poupardin C, Chaussade S, Peyrin-Biroulet L, Abitbol V.
     Diagnostic delay in a French cohort of Crohn’s disease patients.
     Crohns Colitis, 2014, pii: S1873-9946(14)00042-7
215. Narula N, Peyrin-Biroulet L, Colombel JF.
     Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?
     Gastroenterology, 2014, 146, 608-611
216. Panés J, O’Connor M, Peyrin-Biroulet L, Irving P, Petersson J, Colombel JF.
     Improving quality of care in inflammatory bowel disease: What changes can be made today?
     Crohns Colitis, 2014, 8, 919-926
217. Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X.
     Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.
     Bowel Dis., 2014, 20, 1288-1295
218. Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.
     Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
     Gastroenterol. Hepatol., 2014, 12, 80-84.e2
219. Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S.
     Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
     J. Gastroenterol., 2014, 109, 1250-1256
220. Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, Peyrin-Biroulet L, Marteau P, Cadiot G, Laharie D, Boureille A, De Vos M, Savoye G, Rahier JF, Carbonnel F, Bonaz B, Colombel JF, Bouhnik Y.
     Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease.
     Aliment Pharmacol Ther. 2014, 40, 363-73
221. Spinelli A, Fiorino G, Bazzi P, Sacchi M, Bonifacio C, de Bastiani S, Malesci A, Balzarini L, Peyrin-Biroulet L, Montorsi M, Danese S
     Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn’s disease ;
     Gastrointest. Surg., 2014, 18, 83-90
222. Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L
     Addressing current treatment challenges in Crohn’s disease in real life: a physician’s survey
     . Liver Dis., 2014, 46, 1066-1071
223. Williams CJ, Peyrin-Biroulet L, Ford AC
     Systematic review with meta-analysis : malignancies ith anti-tumour necrosis factor a-therapy in inflammatory bowel disease;
     Pharmacol. Ther., 2014, 39, 447-458

224. Carbonnel F, Carbonne JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, FäFrtti M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Erre Miche H, Laharie D; European Crohn’u and Colitis Organisation and the Groupe d’Étude Thérapeutique des Affections Inflammatoires Digestives.
     Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis
     Gastroenterology, 2015, Nov 26. pii: S0016-5085(15)01726-6. doi: 10.1053/j.gastro.2015.10.050. [Epub ahead of print
225. Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV Jr
     Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn’s Disease: A Systematic Review and Meta-analysis
     Bowel Dis., 2015 [Epub ahead of print]
226. Danese S, Fiorino G, Mary JY, Lakatos PL, D’Haens G, Moja L, D’Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF
     Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn’s Disease: An IOIBD Initiative
     Crohns Colitis, 2015, pii: jjv067. [Epub ahead of print]
227. Danese S, Peyrin-Biroulet L, Fiorino G
     Predicting future disease course in Crohn’s disease by colonoscopy or magnetic resonance: which is the crystal ball?
     Gut, 2015, Jan 28. pii: gutjnl-2014-308919. doi: 10.1136/gutjnl-2014-308919. [Epub ahead of print]
228. Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S
     Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
     Gut, 2015, 64, 243-249
229. Depont F, Berenbaum F, Filippi J, Le Maitre M, Nataf H, Paul C, Peyrin-Biroulet L, Thibout E
     Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review
     PLoS One, 2015, 10, e0145076
230. Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S
     Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn’s Disease
     Crohns Colitis, 2015, pii: jjv080. [Epub ahead of print]
231. Fréling E, Peyrin-Biroulet L, Poreaux C, Morali A, Waton J, Schmutz JL, Guéant JL, Barbaud A
     IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment
     Eur J Gastroenterol Hepatol. 2015, 27, 1200-1208
232. Fumery M, Duricova D, Gower-Rousseau C, Annese V, Peyrin-Biroulet L, Lakatos PL
     Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies
     Pharmacol. Ther., 2015 Nov 18 doi: 10.1111/apt.13478. [Epub ahead of print] Review
233. Fumery M, Jacob A, Sarter H, Michaud L, Spyckerelle C, Mouterde O, Savoye G, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C, Turck D; EPIMAD Group
     Efficacy and safety of adalimumab after infliximab failure in pediatric crohn disease
     Pediatr. Gastroenterol. Nutr., 2015, 60, 744-748
234. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L; and the International Programme to Develop New Indexes for Crohn’s Disease (IPNIC) group; International Programme to Develop New Indexes for Crohn’s Disease IPNIC group
     Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort
     Gut, 2015, Dec 8. pii: gutjnl-2015-310151. doi: 10.1136/gutjnl-2015-310151. [Epub ahead of print]
235. Guinet-Charpentier C, Bilbault C, Kennel A, Perrier P, Peyrin-Biroulet L, Morali A
     Unusual association of myasthenia gravis and ulcerative colitis in a 14-year-old boy
     Pediatr., 2015, 22, 81-83
236. Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA
     Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials
     Gastroenterol. Hepatol., 2015, 13, 2233-2240.e2
237. Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV Jr, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR.
     Risk of Lymphoma in Patients With Inflammatory Bowel Disease Treated With Azathioprine and 6-Mercaptopurine: A Meta-analysis.
     Gastroenterol. Hepatol., 2015, 13, 847-858
238. Luthra P, Peyrin-Biroulet L, Ford AC
     Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease
     Pharmacol. Ther., 2015, 41, 1227-1236
239. Nuij V, Fuhler GM, Edel AJ, Ouwendijk RJ, Rijk MC, Beukers R, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ; Dutch Delta IBD Group
     Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
     Crohns Colitis, 2015, 9, 997-1003
240. Reinhard A, Bressenot A, Dassonneville R, Loywick A, Hot D, Audebert C, Marchal S, Guillemin F, Chamaillard M, Peyrin-Biroulet L, Bezdetnaya L.
     Photodynamic therapy relieves colitis and prevents colitis-associated carcinogenesis in mice.
     Bowel Dis., 2015, 21, 985-995
241. Roblin X, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S
     Combination of C-reactive Protein, Infliximab Trough Levels, and Stable but Not Transient Antibodies to Infliximab Are Associated With Loss of Response to Infliximab in Inflammatory Bowel Disease
     Crohns Colitis., 2015, pii: jjv061. [Epub ahead of print]
242. Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM; Swiss IBD Cohort Study Group
     Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease
     Pharmacol. Ther., 2015, 42, 977-989
243. Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J.
     A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases
     Ther., 2015, 32, 983-1028
244. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM
     Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort
     Bowel Dis. 2015, 21, 1794-1800
245. Williet N, Paul S, Peyrin-Biroulet L, Roblin X
     Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases
     Dis. Sci., 2015, Dec 15. [Epub ahead of print]
246. Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID).
     Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti-Tumor Necrosis Factor Agents
     Gastroenterol. Hepatol., 2015, Sep 30. pii: S1542-3565(15)01317-8. doi: 10.1016/j.cgh.2015.09.018.

247. Allocca M, Fiorino G, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S
     Biologic therapies in ulcerative colitis: primi inter pares?
     Drug Targets, 2016 May 27.
248. Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y; Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group and the Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif
     Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
     Gastroenterol. Hepatol., 2016, Feb 22. pii: S1542-3565(16)00164-6. doi: 10.1016/j.cgh.2016.02.016
249. Blotière PO, Rudant J, Barré A, Racine A, Weill A, Peyrin-Biroulet L, Carbonnel F, Alla F
     Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013).
     Liver Dis., 2016, 48, 620-625
250. Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S.
     Biologic Therapies and Risk of Infection and Malignancy in Patients with Inflammatory Bowel Disease: a Systematic Review and Network Meta-analysis
     Gastroenterol. Hepatol., 2016, pii: S1542-3565(16)30197-5. doi: 10.1016/j.cgh.2016.04.039
251. Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S
     Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
     Medicine (Baltimore), 2016, 95, e2308
252. Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group
     Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
     Pharmacol. Ther., 2016, 43, 252-261
253. Coimbra AJ, Rimola J, O’Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL, Sandborn WJ, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J.
     Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn’s disease, and may help select subjects with active inflammation
     Pharmacol. Ther., 2016, 43, 61-72
254. Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S
     Preventing collateral damage in Crohn’s disease: The Lémann index
     Crohns Colitis, 2016 Jan 7. pii: jjv240. [Epub ahead of print] Review
255. Fumery M, Pariente B, Sarter H, Charpentier C, Armengol Debeir L, Dupas JL, Coevoet H, Peyrin-Biroulet L, dʼAgay L, Gower-Rousseau C, Savoye G; EPIMAD group
     Natural History of Crohn’s Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study
     Bowel Dis., 2016 May 19.
256. Guinet-Charpentier C, Champigneulle J, Williet N, Peyrin-Biroulet L, Morali A
     The association of autoimmune diseases with pediatric ulcerative colitis does not influence its disease course
     J. Gastroenterol., 2016 Jan;51(1):33-40
257. Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F.
     Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
     Crohns Colitis, 2016, 10, 395-401
258. Nahon S, Lahmek P, Paupard T, Lesgourgues B, Chaussade S, Peyrin-Biroulet L, Abitbol V
     Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn’s Disease Patients
     Dis. Sci., 2016 May 20.
259. Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH
     Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases
     Ther., 2016, 159, 110-119
260. Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S.
     Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab
     Crohns Colitis, 2016 Mar 28. pii: jjw067
261. Penninck E, Fumery M, Armengol-Debeir L, Sarter H, Savoye G, Turck D, Pineton de Chambrun G, Vasseur F, Dupas JL, Lerebours E, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C; EPIMAD Group
     Postoperative Complications in Pediatric Inflammatory Bowel Disease: A Population-based Study
     Bowel Dis., 2016, 22, 127-133
262. Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D; le GETAID
     Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy
     Bowel Dis., 2016, 22, 1362-1369
263. Van Assche G, Peyrin-Biroulet L, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S
     Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study
     Liver Dis., 2016, 48, 592-600

TEAM 3 – Metabolism, Integrative genomics & Bioinformatics

1. Baron D, Dubois E, Bihouée A, Teusan R, Steenman M, Jourdon P, Magot A, Péréon Y, Veitia R, Savagner F, Ramstein G, Houlgatte R.
   Meta-analysis of muscle transcriptome data using the MADMuscle database reveals biologically relevant gene patterns.
   BMC Genomics, 2011, 12, 113.
2. Gauchotte G, Coffinet L, Schmitt E, Bressenot A, Hennequin V, Champigneulle J, Vignaud JM
   Salivary gland anlage tumor: a clinicopathological study of two cases.
   Fetal Pediatr. Pathol., 2011, 30, 116-123
3. Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler M.P., Toussaint B, Klein M, Vignaud JM, Bressenot A.
   BRAF, P53 and SOX2 in anaplastic thyroid carcinoma : evidence for multistep carcinogenesis.
   Pathology, 2011, 43, 447-452
4. Namour F, Dobrovoljski G, Chery C, Audonnet S, Feillet F, Sperl W, Guéant JL
   Luminal expression of cubilin is impaired in Imerslund Grasbeck syndrome with compound AMN mutations in intron 3 and exon 7
   Haematologica, 2011, 96, 1715-1719
5. Paris C, Pairon JC, Billon-Galland MA, Vanoni-Espiand H, Godbert B, Martinet Y, Chabot F, Aymard B, Vignaud JM
   Giant cell interstitial pneumonia: report of two cases with high titanium concentration in the lung
   J. Respir. Crit. Care Med., 2011, 184, 1315-1317
6. Perrot A, Luquet I, Pigneux A, Mugneret F, Delaunay J, Harousseau JL, Barin C, Cahn JY, Guardiola P, Himberlin C, Recher C, Vey N, Lioure B, Ojeda-Uribe M, Fegueux N, Berthou C, Randriamalala E, Béné MC, Ifrah N, Witz F; Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang
   Dismal prognostic value of monosomal karyotype in elderly patients with acute myeloid leukemia: a GOELAMS study of 186 patients with unfavorable cytogenetic abnormalities
   Blood, 2011, 118, 679-685
7. Perrot A, Pionneau C, Nadaud S, Davi F, Leblond V, Jacob F, Merle-Béral H, Herbrecht R, Béné MC, Gribben JG, Bahram S, Vallat L
   A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia
   Blood, 2011, 118, e1-15
8. Brion A, Mahe B, Kolb B, Audhuy B, Colombat P, Maisonneuve H, Foussard C, Bureau A, Ferrand C, Lesesve JF, Bene MC, Feugier P.
   Autologous transplantation in CLL patients with B and C Binet stages : final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow
   Transplant, 2012; 47, 542-8.
9. Broséus J, Florensa L, Zipperer E, Schnittger S, Malcovati L, Richebourg S, Lippert E, Cermak J, Evans J, Mounier M, Raya JM, Bailly F, Gattermann N, Haferlach T, Garand R, Allou K, Besses C, Germing U, Haferlach C, Travaglino E, Luno E, Pinan MA, Arenillas L, Rozman M, Perez Sirvent ML, Favre B, Guy J, Alonso E, Ahwij N, Jerez A, Hermouet S, Maynadié M, Cazzola M, Girodon F.
   Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.
   Haematologica, 2012; 97, 1036-41.
10. Gauchotte G, Vignaud JM, Ménard O, Wissler MP, Martinet Y, Siat J, Paris C, Clément-Duchêne C
    A combination of smears and cell block preparations provides high diagnostic accuracy for endobronchial ultrasound-guided transbronchial needle aspiration.
    Virchows Arch., 2012, 461, 505-512
11. Gauchotte G, Vigouroux C, Rech F, Battaglia-Hsu SF, Soudant M, Pinelli C, Civit T, Taillandier L, Vignaud JM, Bressenot A.
    Expression of minichromosome maintenance MCM6 protein in meningiomas is strongly correlated with histologic grade and clinical outcome.
    J. Surg. Pathol., 2012, 36, 283-291
12. Lepretre, T Aurran, B Mahé, B Cazin, O Tournilhac, H Maisonneuve, O Casasnovas, A Delmer, V Leblond, B Royer, B Corront, S Chevret, R Delépine, S Vaudaux, E Van Den Neste, MC Béné, R Letestu, F Cymbalista, P Feugier.
    Excess mortality following FCCam treatment in previously untreated patients with CLL: safety and efficacy in a randomized, multicenter, phase III trial.
    Blood, 2012, 119, 5104-5110.
13. Pellanda H, Forges T, Bressenot A, Chango A, Bronowicki JP, Guéant JL, Namour F
    Fumonisin FB1 treatment acts synergistically with donor deficiency during rat pregnancy to produce alterations of H3- and H4-histone methylation patterns in fetuses.
    Nutr. Food. Res., 2012, 56, 976-985
14. Pellanda H, Namour F, Fofou-Caillierez,M, Bressenot A, Alberto JM, Chéry C, Ayav A, Bronowicki JP, Guéant JL, Forges T
    A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma.
    J. Biochem. Cell. Biol., 2012, 44, 385-392
15. Perrot A, Pionneau C, Azar N, Baillou C, Lemoine FM, Leblond V, Merle-Béral H, Béné MC, Herbrecht R, Bahram S, Vallat L
    Waldenström’s macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders
    Blood Cancer J. 2012 Sep 7;2:e88

16. Broséus J, Alpermann T, Wulfert M, Brichs LF, Jeromin S, Lippert E, Rozman M, Lifermann F, Grossmann V, Haferlach T, Germing U, Luño E, Girodon F, Schnittger S;
    MPN and MPNr-EuroNet (COST Action BM0902). Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    2013; 27, 1826-1831
17. Gauchotte G, Lacomme S, Brochin L, Tournier B, Cahn V, Monhoven N, Piard F, Klein M, Martinet N, Rochette-Egly C, Vignaud JM
    Retinoid acid receptor expression is helpful to distinguish between adenoma and well-differentiated carcinoma in the thyroid.
    Virchows Arch., 2013, 462, 619-632
18. Gauchotte G, Marie B, Gallet P, Nguyen DT, grandhaye M, Jankowski R, Vignaud JM
    Respiratory epithelial adenomatoid hamartoma : a poorly recognized entity with mast cell ercruitment and frequently associated with nasal polyposis ;
    J. Surg. Pathol., 2013, 37, 1678-1685
19. Gauchotte G, Wissler MP, Casse JM, Pujo J, Minetti C, Gisquet H, Vigouroux C, Plénat F, Vignaud JM, Martrille L.
    FVIIIra, CD15, and tryptase performance in the diagnosis of skin stab wound vitality in forensic pathology.
    J. Legal. Med., 2013, 127, 957-965
20. Godbert B, Wissler MP, Vignaud JM
    Desquamative interstitial pneumonia: an analytic review with an emphasis on aetiology.
    Respir. Rev., 2013, 22, 117-23

21. Broséus J, Lippert E, Klampfl T, Jeromin S, Zipperer E, Florensa L, Milosevic JD, Haferlach T, Germing U, Luño E, Schnittger S, Kralovics R, Girodon F.
    Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis.
    Leukemia, 2014, 28, 1374-6
22. Broséus J, Park JH, Carillo S, Hermouet S and Girodon F.
    Presence of calreticulin mutations in JAK2-negative polycythemia vera.
    Blood, 2014, 124, 3964-6
23. Elakoum R, Gauchotte G, Oussalah A, Wissler MP, Clément-Duchâne C, Vignaud JM, Guéant JL, Namour F
    CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features.
    Biochimie, 2014, 97, 201-218
24. Jankowski R, Kuntzler S, Boulanger N, Morel O, Tisserant J, Benterkia N, Vignaud JM
    Is pneumosinus dilatans an osteogenic disease that mimics the formation of a paranasal sinus?
    Radiol. Anat., 2014, 36, 429-437
25. Chen G, Broséus J, Hergalant S, Donnart A, Chevalier C, Bolaños-Jiménez F, Guéant JL, Houlgatte R
    Identification of master genes involved in liver key functions through transcriptomics and epigenomics of methyl donor deficiency in rat: relevance to nonalcoholic liver disease
    Nutr. Food Res., 2015, 59, 293-302

26. Delaunay-Lemarie C, Vincourt JB, Marie B, Battaglia-Hsu SF, Etienne S, Sirveaux F, Nguyen Thi PL, Magdalou J, Vignaud JM, Gauchotte G
    In malignant cartilagenous tumors, immunohistochemical expression of procollagen PC1CP peptide is higher and that of PC2CP lower than in benign cartilaginous lesions
    Virchows Arch., 2015, 467, 329-37
27. Feugier P.
    A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin’s lymphomas
    Future Oncol. 2015, 11, 1327-1342
28. Frotscher B, Salignac S, Muller M, Latger-Cannard V, Feugier P, Lesesve JF
    Interference of blast cell fragments with automated platelet counting
    J. Lab. Hematol. 2015, 37, 613-619
29. Jeannesson-Thivisol E, Feillet F, Chéry C, Perrin P, Battaglia-Hsu SF, Herbeth B, Cano A, Barth M, Fouilhoux A, Mention K, Labarthe F, Arnoux JB, Maillot F, Lenaerts C, Dumesnil C, Wagner K, Terral D, Broué P, de Parscau L, Gay C, Kuster A, Bédu A, Besson G, Lamireau D, Odent S, Masurel A, Guéant JL, Namour F
    Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness
    Orphanet J Rare Dis, 2015, 10, 158
30. Vigouroux C, Casse JM, Battaglia-Hsu SF, Brochin L, Luc A, Paris C, Lacomme S, Gueant JL, Vignaud JM, Gauchotte G
    Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma.
    Lung Cancer, 2015, 89, 189-196

31. Broséus J, Chen G, Hergalant S, Ramstein G, Mounier N, Guéant JL, Feugier P, Gisselbrecht C, Thieblemont C, Houlgatte R
    Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses
    Oncotarget, 2016, Jun 2. doi: 10.18632/oncotarget.9793
32. Casse JM, Martrille L, Vignaud JM, Gauchotte G
    Skin wounds vitality markers in forensic pathology: An updated review
    Med Sci Law, 2016, 56, 128-137
33. Lesesve JF, Broséus J.
    Confusing Hairy Cells in a Case of IgG Kappa Plasma Cell Leukemia.
    Clin Lab., 2016, 62, 749-50
34. Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, Bernard M, Stamatoullas A, Borel C, Bouabdallah K, Nicolas-Virelizier E, Fournier M, Morschhauser F, Brice P.
    Lymphoma Study Association (LYSA). Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
    , 2016; 101, 466-73.

35. Baron D, Bihouée A, Teusan R, Dubois E, Savagner F, Steenman M, Houlgatte R, Ramstein G.
    MADGene: retrieval and processing of gene identifier lists for the analysis of heterogeneous microarray datasets.
    , 2011, 27, 725-726.
36. Baron D, Magot A, Ramstein G, Steenman M, Fayet G, Chevalier C, Jourdon P, Houlgatte R, Savagner F, Pereon Y.
    Immune response and mitochondrial metabolism are commonly deregulated in DMD and aging skeletal muscle.
    PLoS One. 2011, 6, e26952.
37. Chetty R, Serra S, Gauchotte G, Märkl B, Agaimy A.
    Sclerosing nodular lesions of the gastrointestinal tract containing large numbers of IgG4 plasma cells.
    Pathology, 2011, 43, 31-35
38. Durrieu F, Geneviève F, Arnoulet C, Brumpt C, Capiod JC, Degenne M, Feuillard J, Garand R, Kara-Terki A, Kulhein E, Maynadié M, Ochoa-Noguera ME, Plesa A, Roussel M, Eghbali H, Truchan-Graczyk M, de Carvalho Bittencourt M, Feugier P, Béné MC.
    Normal levels of peripheral CD19 (+) CD5 (+) CLL-like cells : toward a defined threshold for CLL follow-up-a GEIL-GOELAMS study.
    Cytometry B. Clin. Cytom., 2011; 80, 346-353
39. Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, Feugier P, Ferme C, Ysebaert L, Gabarre J, Herbrecht R, Janvier M, Van Den Neste E, Morschhauser F, Casasnovas O, Ghesquieres H, Anglaret B, Brechignac S, Haioun C, Gisselbrecht C.
    Survival impact of rituximab combined with ACVBP and upfront consolidative autotransplantation in high risk diffuse large B-cell lymphoma for GELA.
    Haematologica, 2011; 96, 1136-1143
40. Herin F, Paris C, Levant A, Vignaud MC, Sobaszek A, Soulat JM.
    Links between nurses’ organisational work environment and upper limb musculoskeletal symptoms: independently of effort-reward imbalance! The ORSOSA study.
    Pain, 2011, 152, 2006-2015
41. Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morschhauser F, Gisselbrecht C, Mounier N.
    Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplant.
    Leuk Lymphoma, 2011, 52, 1239-1248
42. Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud JM, Flejou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, Selva E, Poudenx M, Sibon S, Kelhef S, Venissac N, Jais JP, Mouroux J, Molina TJ, Hofman P
    Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker.
    Cancer Res., 2011, 17, 827-835
43. Hofman VJ, Ilie MI, Bonnetaud C, Selva E, Long E, Molina T, Vignaud JM, Flejou JF, Lantuejoul S, Platon E, Butori C, Mourad N, Poudenx M, Bahadoran P, Sibon S, Guevara N, Santini J, Venissac N, Mouroux J, Vielh P, Hofman PM
    Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method : promises and pitfalls.
    J. Clin. Pathol., 2011, 135, 146-156
44. Le Pennec S, Mirebeau-Prunier D, Boutet-Bouzamondo N, Jacques C, Guillotin D, Lauret E, Houlgatte R, Malthièry Y, Savagner F.
    Nitric oxide and calcium participate in the fine regulation of mitochondrial biogenesis in follicular thyroid carcinoma cells.
    Biol. Chem., 2011, 286, 18229-18239.
45. Perrin J, Ranta D, Empereur F, Vigneron C, Feugier P, Lecompte T.
    Polymorphouclear neutrophils from JAK2 (V617F) positive MPD patients do not support hypercoagulability:A study with calibrated automated thrombography (CAT).
    Blood Cells Mol. Dis., 2011, 46, 235-238
46. Quillé ML, Carat S, Quéméner-Redon S, Hirchaud E, Baron D, Benech C, Guihot J, Placet M, Mignen O, Férec C, Houlgatte R, Friocourt G.
    High-throughput analysis of promoter occupancy reveals new targets for Arx, a gene mutated in mental retardation and interneuronopathies.
    PLoS One. 2011, 6, :e25181.
47. Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, Costes V, Bauchet L; Société Française de Neuropathologie (SFNP), Société Française de Neurochirurgie (SFNC); Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC); Association des Neuro-Oncologues d’Expression Française (ANOCEF) (dont Vignaud JM).
    French brain tumor database: 5-year histological results on 25 756 case.
    Brain Pathol., 2011, 21, 633-644
48. Rolland D, Bouamrani A, Houlgatte R, Barbarat A, Ramus C, Arlotto M, Ballester B, Berger F, Felman P, Callet-Bauchu E, Baseggio L, Traverse-Glehen A, Brugière S, Garin J, Coiffier B, Berger F, Thieblemont C.
    Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometry.
    Lymphoma, 2011, 52, 648-58.
49. Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, Feugier P, Bouabdallah R, Catalano JV, Brice P, Caballero D, Haioun C, Pedersen LM, Delmer A, Simpson D, Leppa S, Soubeyran P, Hagenbeek A, Casasnovas O, Intragumtornchai T, Fermé C, da Silva MG, Sebban C, Lister A, Estell JA, Milone G, Sonet A, Mendila M, Coiffier B, Tilly H.
    Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA) : a phase 3, randomised controlled trial.
    Lancet, 2011, 377, 42-51.
50. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.
    The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    J Clin Oncol, 2011; 29, 4079-4087.
51. Verine J, Sandid W, Miquel C, Vignaud JM, Mongiat-Artus P.
    Sporadic hemangioblastoma of the kidney: an underrecognized pseudomalignant tumor?
    Am J Surg Pathol., 2011, 4, 623-4

52. Chen M, de Carvalho Bittencourt M, Feugier P, Faure GC, Béné MC.
    Active Toll-Like Receptor-7 triggring of chronic lymphocytique leukemia B-cells by Imiquimod.
    Lymphoma, 2012, 53, 739-742.
53. Cuccuini W, Briere J, Mounier N, Voelker HU, Rosenwald A, Sundstrom C, Cogliatti S, Hirchaud E, Ysebaert L, Bron D, Soulier J, Gaulard P, Houlgatte R, Gisselbrecht C, Thieblemont C.
    MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
    Blood, 2012, 119, 4619-4624
54. Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, Mounier N, Gallamini A, Feugier P, Soubeyran P, Colombat P, Laurent G, Berenger N, Casasnovas RO, Vera P, Paone G, Xerri L, Salles G, Haioun C, Meignan M.
    Impact of (18) Fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d’Etudes des Lymphomes de l’Adulte and GOELAMS.
    Clin. Oncol., 2012, 30, 4317-4322
55. Feuerstein P, Puard V, Chevalier C, Teusan R, Cadoret V, Guerif F, Houlgatte R, Royere D
    Genomic assessment of human cumulus cell marker genes as preditors od oocyte developmental competence : impact of various experimental factors
    Plos One, 2012, 7, e40449
56. Gallet P, Marcon N, Georgel T, Vignaud JM, Parietti-Winkler C, Jankowski R.
    Chondroid chordoma and nasal adenocarcinoma: an exceptional association.
    Case Rep. Oncol. Med., 2012, 2012, 861217
57. Ghesquières H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, Soubeyran P, Perrot A, Brice P, Bouabdallah R, Sonet A, Dupuis J, Casasnovas O, Catalano JV, Delmer A, Jardin F, Verney A, Dartigues P, Salles G.
    Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms
    Blood, 2012, 120, 2650-2657
58. Gonzalez M, Vignaud JM, Clement-Duchene C, Luc A, Wild P, Bertrand O, Thiberville L, Martinet Y, Benichou J, Paris C
    Smoking, occupational risk factors, and bronchial tumor location: a possible impact for lung cancer computed tomography scan screening.
    Thorac. Oncol., 2012, 7, 128-136
59. Hofman V, Long E, Ilie M, Bonnetaud C, Vignaud JM, Fléjou JF, Lantuejoul S, Piaton E, Mourad N, Butori C, Selva E, Marquette CH, Poudenx M, Sibon S, Kelhef S, Vénissac N, Jais JP, Mouroux J, Molina TJ, Vielh P, Hofman P
    Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method
    Cytopathology, 2012, 23, 30-38
60. Idbaih A, Ducray F, Dehais C, Courdy C, Carpentier C, de Bernard S, Uro-Coste E, Mokhtari K, Jouvet A, Honnorat J, Chinot O, Ramirez C, Beauchesne P, Benouaich-Amiel A, Godard J, Eimer S, Parker F, Lechapt-Zalcman E, Colin P, Loussouarn D, Faillot T, Dam-Hieu P, Elouadhani-Hamdi S, Bauchet L, Langlois O, Le Guerinel C, Fontaine D, Vauleon E, Menei P, Fotso MJ, Desenclos C, Verrelle P, Ghiringhelli F, Noel G, Labrousse F, Carpentier A, Dhermain F, Delattre JY, Figarella-Branger D; POLA Network. (dont Vignaud JM)
    SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.
    PLoS One, 2012, 7, e45950. Erratum in: PLoS One. 2013;8(5).
61. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH
    Treatment of older patients with mantle-cell lymphoma.
    Engl. J. Med., 2012, 367, 520-31
62. Lorentz C, Marie B, Vignaud JM, Jankowski R
    Respiratory epithelial adenomatoid hamartomas of the olfactory clefts.
    Arch. Otorhinolaryngol., 2012, 269, 847-852
63. Lorentz C, Rivier A, Debourgogne A, Sokolowska-Gillois J, Vignaud JM, Jankowski R, Machouart M
    Ethmoido-maxillary sinusitis caused by the basidiomycetous fungus Schizophyllum commune.
    Mycoses, 2012, 55, e8-12
64. Mounier N, Heutte N, Thieblemont C, Briere J, Gaulard P, Feugier P, Ghesquieres H, Van Den Neste E, Robu D, Tilly H, Bouabdallah R, Safar V, Coiffier B
    Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH 98-5 Trial; Groupe d’Etude des Lymphomes de l’Adulte (GELA). Clin Lymphoma Myeloma Leuk., 2012, 12, 151-154
65. Van den Neste E, Letestu R, Aurran-Schleinitz T, Ysebaert L, Feugier P, Leprêtre S, Dartigeas C.
    Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukaemia: where do we stand ?
    Lymphoma, 2012, 53, 362-70.
66. Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d’Etude des Lymphomes de l’Adulte (GELA).
    Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
    Haematologica, 2013, 98,1107-14.
67. Colman H, Le Berre-Scoul C, Hernnadez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C.
    Genome-wide analysis of host mRNA translation during hepatitis C virus infection;
    Virol., 2013, 87, 6688-6677
68. Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X
    Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma
    Cancer, 2013, 119, 3680-6
69. Hadife N, Nemos C, Frippiat JP, Hamadé T, Perrot A, Dalloul A.
    Interleukin-24 mediates apoptosis in human B-cells through early activation of cell cycle arrest followed by late induction of the mitochondrial apoptosis pathway.
    Lymphoma, 2013, 54, 587-597
70. Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, von Deimling A, Emile JF, Hofman P
    Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients.
    Oncol., 2013, 24, 742-748
71. Jungmann H, Godbert B, Wissler MP, Regent D, Vignaud JM, Bavelele Z, Martinet Y
    diffuse pulmonary ossification in a patient exposed to silica.
    Respir. Rev., 2013, 22, 189-190
72. Largeot A, Paggetti J, Broséus J, Aucagne R, Lagrange B, Martin RZ, Berthelet J, Quéré R, Lucchi G, Ducoroy P, Bastie JN, Delva L.
    Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells
    Biophys. Acta, 2013, 1833, 3054-3063
73. Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G, Wenger M, Wassner-Fritsch E, Salles GA
    Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results from the Phase II GAUGUIN Study
    Clin. Oncol., 2013, 31, 2912-9.
74. Nguyen DT, Gauchotte G, Nguyen-Thi PL, Jankowski R.
    Does surgery of the olfactory clefts modify the sense of smell?
    Am J Rhinol Allergy., 2013, 27, 317-21
75. Ribrag V, Tilly H, Casasnovas O, Bosly A, Bouabdallah R, Delarue R, Boue F, Bron D, Feugier P, Haioun C, Offner F, Coiffier B.
    Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma : a randomized phase II trial from the Grope d’Etude des Lymphomes de l’Adulte (GELA).
    J. Cancer; 2013; 49, 904-10.
76. Rolland AD, Lardenois A, Goupil AS, Lareyre JJ, Houlgatte R, Chalmel F, Le Gac F
    Profiling of androgen response in rainbow trout pubertal testis : relevance to male gonad development and spermatogenesis;
    Plos One, 2013, 8, e53302
77. Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, Molina TJ, Jardin F, Terriou L, Haioun C, Coiffier B.
    Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma.
    Leukemia, 2013, 27,252-5.
78. Trebouet A, Marchand T, Lemal R, Gyan E, Broussais-Guillaumot F, Guillermin Y, Monjanel H, Salles G, Le Gouill S, Godmer P, Fruchart C, Damaj G, Feugier P, Thieblemont C, Maynadié M, Monnereau A, Troussard X, Rossille D, Lamy T, Houot R.
    Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA.
    Oncol., 2013, 24, 2612-8.
79. Clément-Duchêne C, Alla F, Gauchotte G, Marie B, Carnin C, Menard O, Vignaud JM, Martinet Y.
    Is there a relationship between the presence of lung mucosa preinvasive lesions and lung cancer incidence? Influence of tobacco consumption.
    Lung Cancer. 2014, 84, 134-138
80. Cornet E, Delmer A, Feugier P, Garnache-Ottou F, Ghez D, Leblond V, Levy V, Maloisel F, Re D, Zini JM, Troussard X. French Societe of Haematology
    Recommendations of the SFH (French Societe of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia.
    Hematol., 2014, 93, 1977-1983
81. Cornet E, Tomowiak C, Tanguy-Schmidt A, Lepretre S, Dupuis J, Feugier P, Devidas A, Mariette C, Leblond V, Thiéblemont C, Validire-Charpy P, Sutton L, Gyan E, Eisenmann JC, Cony-Makhoul P, Ysebaert L, Troussard X; Société Française d’Hématologie
    Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia
    J. Haematol., 2014, 166, 390-400
82. Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, Carpentier C, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A; the POLA Network.
    Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.
    Neuro Oncol., 2014, 16, 1244-1254
83. Hospital MA, Prebet T, Bertoli S, Thomas X, Tavernier E, Braun T, Pautas C, Perrot A, Lioure B, Rousselot P, Tamburini J, Cluzeau T, Konopacki J, Randriamalala E, Berthon C, Gourin MP, Recher C, Cahn JY, Ifrah N, Dombret H, Boissel N
    Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
    Blood, 2014, 124, 1312-1319
84. Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, Mouroux J, Marquette CH, Hofman P
    « Sentinel » circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease
    PLoS One, 2014, 9, e111597
85. Ilie MI1, Long-Mira E, Hofman V, Mouroux J, Vignaud JM, Gauchotte G, Begueret H, Merlio JP, Emile JF, Hébuterne X, Hofman P.
    BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Pathology, 2014, 46, 311-315
86. Nguyen DT, Gauchotte G, Arous F, Vignaud JM, Jankowski R
    Respiratory epithelial adenomatoid hamartoma of the nose: an updated review
    J. Rhinol. Allergy, 2014, 28, 187-192
87. Nguyen DT, Nguyen-Thi PL, Gauchotte G, Arous F, Vignaud JM, Jankowski R.
    Predictors of respiratory epithelial adenomatoid hamartomas of the olfactory clefts in patients with nasal polyposis.
    Laryngoscope, 2014, 124, 2461-2465
88. Rech F, Rigau V, Fabbro M, Kerr C, Gauchotte G, Taillandier L, Duffau H
    A nonradiated grade II glioma that underwent delayed malignant transformation to a gliosarcoma with meningeal growth and dissemination
    Neurol. Surg. A Cent. Eur. Neurosurg., 2014, 5, 485-90
89. Reyes-Botero G, Dehais C, Idbaih A, Martin-Duverneuil N, Lahutte M, Carpentier C, Letouzé E, Chinot O, Loiseau H, Honnorat J, Ramirez C, Moyal E, Figarella-Branger D, Ducray F; POLA Network (dont Vignaud JM).
    Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.
    Neuro Oncol., 2014, 6, 662-670
90. Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, French M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, Salles G.
    Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
    Br J Haematol., 2014, 164, 659-67
91. Xerri L, Bachy E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Brousse N, Rousselet MC, Foussard C, Brice P, Feugier P, Morschhauser F, Sonet A, Olive D, Salles G; LYSA study.
    Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.
    Pathol., 2014, 45, 2085-2093

92. Baron D, Ramstein G, Chesneau M, Echasseriau Y, Pallier A, Paul C, Deguque N, hernandez-Fuentes MP, Sanchez-Fueyo A, Newell KA, Giral M, Soulillou JP, Houlgatte R, Brouard S
    A common gene signature across multiple studies identifies biomarkers and functional regulation in tolerance to renal allograft.
    Kidney Int., 2015, 887,98-995
93. Delfau-Larue MH, Klapper W, Berger F, Jardin F, Briere J, Salles G, Casasnovas O, Feugier P, Haioun C, Ribrag V, Thieblemont C, Unterhalt M, Dreyling M, Macintyre E, Pott C, Hermine O, Hoster E; European Mantle Cell Lymphoma Network.
    High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
    Blood, 2015, 126, 604-611
94. Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network
    Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis
    Brain Pathol, 2015, 25, 418-428
95. Fornecker LM, Aurran-Schleinitz T, Michallet AS, Cazin B, Guieze R, Dilhuydy MS, Zini JM, Tomowiak C, Lepretre S, Cymbalista F, Brion A, Feugier P, Delmer A, Leblond V, Ysebaert L
    Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience
    J. Hematol. 2015, 90, 511-514
96. Jankowski R, Russel A, Gallet P, Henrot P, Vignaud JM, Nguyen DT
    Olfactory neuroblastoma behavior inside and outside the olfactory cleft
    Radiol. Anat., 2015, 37, 507-515
97. Janvier L, Olivier P, Blonski M, Morel O, Vignaud JM, Karcher G, Taillandier L, Verger A
    Correlation of SUV-Derived Indices With Tumoral Aggressiveness of Gliomas in Static 18F-FDOPA PET: Use in Clinical Practice
    Clin Nucl Med., 2015, 4, e429-35
98. Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, Moccia AA, Brice P, Chavez EA, Kyle AH, Scott DW, Sanders AD, Fabiani B, Slack GW, Minchinton AI, Haioun C, Connors JM, Sehn LH, Steidl C, Gascoyne RD, Salles G
    The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association
    Clin Cancer Res, 2015, 21, 3428-3435
99. Labreche K, Simeonova I, Kamoun A, Gleize V, Chubb D, Letouzé E, Riazalhosseini Y, Dobbins SE, Elarouci N, Ducray F, de Reyniès A, Zelenika D, Wardell CP, Frampton M, Saulnier O, Pastinen T, Hallout S, Figarella-Branger D, Dehais C, Idbaih A, Mokhtari K, Delattre JY, Huillard E, Mark Lathrop G, Sanson M, Houlston RS; POLA Network (dont G. Gauchotte)
    TCF12 is mutated in anaplastic oligodendroglioma
    Nat Commun, 2015, 6, 7207
100. Lantuejoul S, Rouquette I, Blons H, Le Stang N, Ilie M, Begueret H, Grégoire V, Hofman P, Gros A, Garcia S, Monhoven N, Devouassoux-Shisheboran M, Mansuet-Lupo A, Thivolet F, Antoine M, Vignaud JM, Penault-Llorca F, Galateau-Sallé F, McLeer-Florin A French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas
     Respir. J., 2015, pii: ERJ-01199-2014.
     
101. Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Sallé F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F
     SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas
     Nat Genet, 2015, 47, 1200-1205
102. Lesesve JF, Tardy S, Frotscher B, Latger-Cannard V, Feugier P, De Carvalho Bittencourt M
     Combination of CD160 and CD200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature B-cell neoplasms
     Int J Lab Hematol, 2015, 37, 486-494
103. Maraldo MV, Giusti F, Vogelius IR, Lundemann M, van der Kaaij MA, Ramadan S, Meulemans B, Henry-Amar M, Aleman BM, Raemaekers J, Meijnders P, Moser EC, Kluin-Nelemans HC, Feugier P, Casasnovas O, Fortpied C, Specht L; European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group
     Cardiovascular disease after treatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials.
     Lancet Haematol, 2015, 2, e492-502
104. Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, Miquel C, Uro-Coste E, Godfraind C, Lechapt-Zalcman E, Labrousse F, Gauchotte G, Silva K, Jouvet A, Figarella-Branger D
     Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours
     Appl. Neurobiol., 2015, 41, 403-408
105. Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, Michallet AS, Feugier P, Guieze R, Levy V, Delmer A.
     Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
     Am J Hematol, 2015, 90, 204-207
106. Sorin T, Eluecque H, Gauchotte G, De Runz A, Chassagne JF, Mansuy L, Gisquet H, Simon E
     Pilomatrix Carcinoma of the scalp. A case report and review of the literature.
     Chir. Plast. Esthet., 2015,:242-246
107. Trechot P, Jouzeau JY, Brouillard C, Scala-Bertola J, Petitpain N, Cuny JF, Gauchotte G, Schmutz JL, Barbaud A.
     Role of nicotinic acid and nicotinamide in nicorandil-induced ulcerations: from hypothesis to demonstration.
     Wound J., 2015, 12, 527-530
108. Ysebaert L, Feugier P, Michallet AS
     Management of elderly patients with chronic lymphocytic leukemia in the era of targeted therapies
     Curr Opin Oncol, 2015, 27, 365-70

109. Colman H, Berre-Scoul CL, Hernandez C, Pierredon S, Bihouée A, Houlgatte R, Vagner S, Rosenberg AR, Féray C
     Correction for Colman et al., Genome-Wide Analysis of Host mRNA Translation during Hepatitis C Virus Infection
     Virol., 2016, 90, 5846
110. Dartigeas C, Van Den Neste E, Berthou C, Maisonneuve H, Leprêtre S, Dilhuydy MS, Béné MC, Nguyen-Khac F, Letestu R, Cymbalista F, De Guibert S, Aurran T, Laribi K, Vilque JP, Tournilhac O, Delmer A, Feugier P, Cazin B, Michallet AS, Lévy V, Troussard X, Delepine R, Tavernier E, Colombat P, Leblond V
     Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia
     Leuk Lymphoma, 2016, 57, 328-334
111. Dequeker EM, Keppens C, Egele C, Delen S, Lamy A, Lemoine A, Sabourin JC, Andrieu C, Ligtenberg M, Fetique D, Tops B, Descarpentries C, Blons H, Denoux Y, Aube C, Penault-Llorca F, Hofman P, Leroy K, Le Marechal C, Doucet L, Duranton-Tanneur V, Pedeutour F, Soubeyran I, Côté JF, Emile JF, Vignaud JM, Monhoven N, Haddad V, Laurent-Puig P, van Krieken H, Nowak F, Lonchamp E, Bellocq JP, Rouleau E
     Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer
     Mol. Diagn., 2016 , 18, 205-214
112. Figarella-Branger D, Mokhtari K, Dehais C, Carpentier C, Colin C, Jouvet A, Uro-Coste E, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A, Delattre JY; POLA Network
     Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas
     Oncol, 2016,18, 888-90
113. Filliatre L, Broséus J, Pissard S, Mekki C, Feugier P, Perrin J
     Amyl nitrite inhalation, a « volatile » anemia
     Am J Hematol. 2016 , 91, 448.
114. Gagez AL, Tuaillon E, Cezar R, Dartigeas C, Mahé B, Letestu R, Maisonneuve H, Gouilleux-Gruart V, Bollore K, Ferrant E, Aurran T, Feugier P, Leprêtre S, Cartron G
     Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups
     Blood Cancer J., 2016, 6, e389
115. Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M; European Mantle Cell Lymphoma Network.
     Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
     Lancet, 2016 Jun 13. Epub ahead of print
116. Le Pennec S, Mirebeau-Prunier D, Boutet-Bouzamondo N, Jacques C, Guillotin D, Lauret E, Houlgatte R, Malthiery Y and Savagner F.
     Nitric Oxide and Calcium Participate in the Fine Regulation of Mitochondrial Biogenesis in Follicular Thyroid Carcinoma Cells.
     Biol. Chem., 2011, 286, 18229-18239.
117. Lepretre S, Dartigeas C, Feugier P, Marty M, Salles
     Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies
     Lymphoma, 2016, 57, 852-865
118. Sarkozy C, Trneny M, Xerri L, Wickham N, Feugier P, Leppa S, Brice P, Soubeyran P, Gomes Da Silva M, Mounier C, Offner F, Dupuis J, Caballero D, Canioni D, Paula M, Delarue R, Zachee P, Seymour J, Salles GA, and Tilly H.
     Risk factors and outcomes of follicular lymphoma patients with histological transformation after response to first-line immunochemotherapy in the PRIMA study.
     Clin. Oncol., 2016, 34, 2575-2582
119. Sigoillot SM, Bourgeois F, Karmouch J, Molgó J, Dobbertin A, Chevalier C, Houlgatte R, Léger J, Legay C
     Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency
     FASEB J, 2016, 30, 2382-2399
120. Sorin T, Vignaud JM, Colson T, Gauchotte G, De Runz A, Brix M, Cuny JF, Simon E
     Zosteriform configuration of multiple eccrine spiradenomas of the scalp
     Chir. Plast. Esthet., 2016, 61, 65-68 

121. Debourgogne A, Goehringer F, Umhang G, Gauchotte G, Hénard S, Boué F, May T, Machouart M.
     Primary cerebral alveolar echinococcosis: mycology to the rescue.
     Clin. Microbiol, 2014, 52, 692-694
122. Liu Y, Maureira P, Gauchotte G, Falanga A, Marie V, Olivier A, Groubatch F, Gu C, Marie PY, Tran N
     Effect of chronic left ventricular unloading on myocardial remodeling: Multimodal assessment of two heterotopic heart transplantation techniques
     Heart Lung Transplant., 2015, 34, 594-603